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ABSTRACT 
Leishmaniasis is a neglected tropical disease caused by obligate intra-macrophagic 
protozoa that has a higher incidence in less developed countries and is responsible for 
high mortality. Since there is no commercially available human vaccine against 
leishmaniasis the control of this disease is dependent on drug therapy and vector control. 
However, current therapies are far from satisfactory, especially due to the emergence of 
resistances, elevated toxicity and increased prevalence of human immunodeficiency virus 
(HIV)-Leishmania co-infections [1-3]. Thus, it is of great importance to develop alternative 
treatments, like nanotechnology-based drug delivery systems, which may reduce toxicity 
and side effects of the drugs, and enhance their efficacy. 
Active targeting of polymeric nanoparticles to mannose receptor (MR), an endocytic 
receptor highly expressed on antigen presenting cells (APCs) (macrophages and dendritic 
cells (DCs)), seems to be a good strategy for targeting and delivery of drugs in the 
treatment of visceral leishmaniasis (VL). One of the drugs currently used in the treatment 
of VL is amphotericin B (AmB), however its use have some drawbacks, including the high 
toxicity, the high costs associated with its use, the limited availability in some areas, 
difficulties associated with the administration, prolonged duration of therapy and the 
severe side effects [1, 3-4]. Thus in order to improve AmB efficacy as an antileishmanial 
drug and reduce its toxicity, the first part of this work aims to develop and characterize a 
nanoparticulate system targeting MR in APCs, the target cells in VL, being that the 
strategy chosen involves: (1) the preparation of unloaded mannose-coated poly( lactic-co-
glycolic acid) (M-PLGA) nanoparticles by three different techniques physical adsorption 
(PA), one-step chemical reaction (CR1) and two-step chemical reaction (CR2); (2) use of 
the developed nanoparticulate system to encapsulate AmB and evaluate their in vitro 
efficacy against Leishmania –infected macrophages; (3) assessment of the new targeted-
nanoformulations uptake by APCs. 
Empty and AmB- loaded PLGA nanoparticles were prepared by the nanoprecipitation 
method [5] and for the three different techniques (PA, CR1 and CR2) used to prepare 
empty M-PLGA nanoparticles, PA and CR1 were choose to conjugate mannose with 
AmB-loaded PLGA nanoparticles. 
The AmB-loaded M-PLGA nanoparticles, prepared by PA and CR1, present a mean 
diameter of 200.2 nm and 190.8 nm, respectively, low PDI (<0.1), anionic surface charge 
(-14.7 mV and -16.2 mV, respectively) and are spherical in shape. The yield associated 
with incorporation level of mannose, determined by phenol-sulfuric acid reaction, is 
around 95% for PA and 98% for CR1. Encapsulation efficiency (E.E.) of 1.8% and 4.1% 
were obtained for nanoparticles prepared by PA and CR1, respectively, which is low as 
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compared with non functionalized PLGA nanoparticles (E.E. ≈ 20%). The AmB-loaded   
M-PLGA nanoparticles, prepared by PA and CR1, exhibited a triphasic release profile. 
The nanoformulations don’t present cytotoxicity against human THP1 differentiated 
macrophages and bone marrow derived macrophages (BMM). The functionalization of 
PLGA nanoparticles leads to an improvement of AmB antileishmanial activity, perhaps 
related with a more efficient uptake. Ex vivo studies clearly demonstrate that FITC-loaded 
M-PLGA nanoparticles present an enhanced uptake by APCs and neutrophils when 
compared with other splenocytes (e.g. lymphocytes). Thus, the data obtained until now 
show that mannosylated nanoformulations, in particular the ones prepared by CR1, could 
have a promising role in the delivery of AmB and consequently in the treatment of VL. 
Based on the fact that active targeting of nanoparticles to MR can potentially improve their 
efficacy in the induction of an immune response [6-8], the second part of this work aims to 
identify the optimum targeted nanoformulation for efficient delivery to APCs, using PLGA 
nanoparticles functionalized with three different sugars, mannose (M), mannan (MN) and 
mannosamine (Ms) and evaluate the extent in which these formulations affect the 
activation status of the cells, as well as the type of response that they will modulate in 
APCs, using flow cytometry. Results show that the functionalization of PLGA 
nanoparticles with ligands that are specifically recognized by MR in APCs, particularly with 
MN and Ms, improve their immunotherapeutic effect, through the induction of a more 
efficient activation of macrophages and DCs, evidenced by the enhanced expression of 
cell surface markers, including CD40, CD80, CD86 and MHC II and by the higher 
production of pro-inflammatory cytokines interleukin (IL)-4, IL-6, IL-12 and tumor necrosis 
factor-alpha (TNF-α), which could lead to the development of a robust immune response. 
Furthermore, fluorescence microscopy results show that, although non-functionalized and 
M-, MN- and Ms- functionalized PLGA nanoparticles are all efficiently internalized by 
macrophages, their distribution pattern is different, being that in the case of MN- and Ms-
PLGA nanoparticles the presence of green dots in the cytoplasm suggests that the uptake 
of these nanoparticles occurs by an endocytic pathway. The obtained results strongly 
suggest that functionalization of PLGA nanoparticles with MN and Ms are a promising 
strategy to target MR in APCs and to promote the development of a robust immune 
response, as a result of the more efficient activation of macrophages and DCs. 
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RESUMO 
A leishmaniose é uma doença tropical negligenciada causada por protozoários 
intracelulares obrigatórios, com uma maior incidência em países em desenvolvimento, 
onde é responsável por uma elevada mortalidade. Uma vez que não existe, até à data, 
uma vacina disponível para a prevenção e o tratamento da leishmaniose em humanos, o 
controlo desta doença está dependente da terapêutica farmacológica e do controlo do 
vector. Contudo, as terapias atualmente disponíveis não são satisfatórias, principalmente 
devido ao aparecimento de resistências, elevada toxicidade e número crescente de casos 
de co-infecção HIV-Leishmania [1-3]. Assim, o desenvolvimento de tratamentos 
alternativos, como por exemplo sistemas de veiculação de fármacos, que permitam 
reduzir a toxicidade e os efeitos secundários dos fármacos, e aumentar a sua eficácia, 
assume uma grande importância. 
O direcionamento de nanopartículas poliméricas para o recetor da manose, um recetor 
endocítico expresso em elevado número nas células apresentadoras de antigénios 
(macrófagos e células dendríticas), representa uma estratégia promissora para aumentar 
a eficiência de fármacos no tratamento da leishmaniose visceral. A anfotericina B é um 
dos fármacos atualmente utilizados no tratamento da leishmaniose visceral, contudo a 
sua utilização tem algumas desvantagens, como a elevada toxicidade, os elevados 
custos, a reduzida disponibilidade deste fármaco em algumas áreas, as dificuldades 
associadas à sua administração, a duração prolongada do tratamento e os efeitos 
secundários indesejáveis [1, 3-4]. Assim, no sentido de aumentar a eficácia da 
anfotericina B no tratamento da leishmaniose visceral e reduzir a sua toxicidade, a 
primeira parte deste trabalho tem como objectivo desenvolver e caracterizar uma 
nanoformulação direcionada para o recetor da manose expresso nas células 
apresentadoras de antigénios. Estas são células alvo na leishmaniose visceral, sendo 
que a estratégia escolhida envolve: (1) preparação de nanopartículas revestidas com 
manose usando três técnicas diferentes, adsorção física, reação química em um passo e 
reacção química em dois passos; (2) utilização da nanoformulação desenvolvida para 
encapsular a anfotericina B e avaliação in vitro da sua atividade anti-parasitária; (3) 
avaliação da internalização das nanoformulação desenvolvidas pelas células 
apresentadoras de antigénios. 
As nanopartículas de poly( lactic-co-glycolic acid) (PLGA) vazias e contendo    
anfotericina B foram preparadas por nanoprecipitação e das três técnicas utilizadas para 
preparar as nanopartículas de manose-PLGA vazias, a adsorção física e a reação 
química em um passo foram as escolhidas para revestir com manose as nanopartículas 
de PLGA contendo anfotericina B. 
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As nanopartículas de manose-PLGA contendo anfotericina B preparadas por adsorção 
física e a reação química em um passo, apresentaram diâmetros médios de 200,2 e 
190,8 nm, respectivamente, baixos índices de polidispersão (<0,1), carga superficial 
negativa (-14,7 mV e -16,2 mV, respectivamente) e uma forma esférica. O nível de 
incorporação da manose foi determinado pela reação do fenol-ácido sulfúrico, tendo-se 
obtido rendimentos de 95% para as nanopartículas preparadas por adsorção física e 98% 
para as preparadas por reação química em um só passo. Eficiências de encapsulação da 
anfotericina B de 1,8% e 4,1% foram obtidas para as nanopartículas preparadas por 
adsorção física e reação química em um passo, respectivamente, valores baixos quando 
comparados com os obtidos para as nanoparticulas de PLGA não revestidas com 
manose (Eficiência de encapsulação≈20%). A anfotericina B encapsulada nas 
nanopartículas de manose-PLGA preparadas por adsorção física e por reação química 
em um só passo apresentaram um padrão de libertação de fármaco trifásico. As 
nanoformulações desenvolvidas não apresentam toxicidade para macrófagos 
diferenciados de monócitos THP-1 e para macrófagos derivados da medula óssea de 
ratinho. O revestimento das nanopartículas de PLGA favorece a actividade antileishmania 
da anfotericina B, o que provavelmente está relacionado com a internalização mais 
eficiente destas nanopartículas. Estudos ex vivo demonstraram que as nanopartículas de 
manose-PLGA contendo fluoresceína são preferencialmente internalizadas pelas células 
apresentadoras de antigénios e neutrófilos, em comparação com outras células (p.e. 
linfócitos). Assim, os resultados obtidos até agora demonstram que as nanoformulações 
manosiladas, em particular as preparadas por reação química em um passo, poderão ter 
um papel promissor na veiculação da anfotericina B e, consequentemente, no tratamento 
da leishmaniose visceral. 
O revestimento das nanopartículas com ligandos que são especificamente reconhecidos 
pelo recetor da manose parece favorecer um desenvolvimento mais eficaz da resposta 
imunológica [6-8]. Assim, o objetivo da segunda parte deste trabalho consiste em utilizar 
nanopartículas de PLGA revestidas com três açúcares diferentes, manose (M), mannan 
(MN) e manosamina (Ms), para identificar o açúcar que influencia a modulação/ativação 
das células apresentadoras de antigénios (macrófagos e células dendríticas). Os 
resultados demonstraram que o revestimento das nanopartículas de PLGA com 
diferentes ligandos, em particular com MN e Ms, favorecem o seu efeito 
imunoterapêutico, uma vez que estimulam uma activação mais eficiente dos macrófagos 
e das células dendríticas, o que é evidenciado pelo aumento na expressão de 
marcadores de superfície celular, incluindo CD40, CD80, CD86 e MHCII e pela elevada 
produção de citocinas pro-inflamatórias (IL-4, IL-6, IL-12 e TNF-α), o que pode favorecer 
o desenvolvimento de uma resposta imunológica intensa. Os resultados de microscopia 
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de fluorescência demonstraram que, apesar de todas as nanopartículas, revestidas ou 
não com M, MN e Ms serem eficientemente internalizadas pelos macrófagos, a sua 
distribuição intracelular é diferente, sendo que, no caso das nanopartículas de MN- e Ms-
PLGA a presença de vesículas no citoplasma sugere que a internalização destas 
nanopartículas ocorre por via endocítica. Os resultados obtidos sugerem que o 
revestimento das nanopartículas de PLGA com MN e Ms constituí uma estratégia 
promissora para direcionar estas nanoformulações para as células apresentadoras de 
antigénios e promover o desenvolvimento de uma resposta imunológica mais eficiente. 
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I. INTRODUCTION 
1.1. Nanotechnology 
The research interest in the area of developing nanotechnology suffered a huge growth in 
the last years. Thus, the concept of “magic bullet” proposed by Paul Ehrlich, Nobel Prize 
for medicine in 1908, is now a reality with the use of nanoparticles as drug targeting 
systems in the treatment of infectious and oncological diseases. Since the first 
descriptions of the use of liposomes [9] and polymeric nanoparticles [10] as drug delivery 
systems until now, a high number of different nanosystems made of lipids or polymers 
emerged (Fig.1). It’s important to note that each of these nanosystems have different 
physicochemical properties and distinct sizes that ranges in the nanoscale, e.g. liposomes 
(80-200 nm), nanoparticles (20-1000 nm), polymer therapeutics (5-25 nm), block 
copolymer micelles (50-200 nm), gold nanoparticles (5-50 nm) and nanosized crystals 
(100-1000 nm) [11]. The use of these nanosystems for therapeutic purposes, to carry a 
drug in the body in a controlled manner from the site of administration to the therapeutic 
target, has been explored at the level of pharmaceutical research. 
 
 
Figure 1 - Main classes of nanosystems used for drug delivery and targeting. Adapted from [11]. 
The nanotechnology has allowed making great advances in the development of drug 
targeting systems for therapeutic applications, however still far from the “magic bullet”. 
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1.2. Nanoparticles 
Nanoparticles are colloidal systems with a particle size in the range of 10 nm - 1 µm and 
are composed of synthetic (polylactic acid (PLA), poly( lactic-co-glycolic acid) (PLGA), etc) 
or natural (e.g. gelatin, albumin and chitosan) polymers. A wide variety of drugs can be 
incorporated in the nanoparticles, including hydrophilic and hydrophobic small drugs, 
vaccines and biological macromolecules [12-13]. To allow their use as drug delivery 
system their components should be biocompatible, biodegradable, non-immunogenic and 
non-toxic. As a result of their small size, nanoparticles present unique properties in terms 
of appearance and application. For example, their small size allows them to be maintained 
in suspension by Brownian motion of the water molecules and they can have a closure 
contact with tissues and cells as a result of their large surface areas [12]. According to the 
process used for their preparation, they can be classified as nanocapsules or 
nanospheres. Nanocapsules are vesicular systems composed by a polymeric shell and an 
inner core where the drug can be dissolved. Nanospheres have a matrix like structure 
where the drug can be entrapped or dispersed [12]. 
The use of nanoparticles and most precisely polymeric nanoparticles, for encapsulation 
and controlled release of different pharmacological active agents, has been extensively 
studied in the last decades, since they favors a controlled release of the drugs, have a 
sub-cellular size, are biocompatible with tissues and cells, biodegradable, non-toxic,    
non-thrombogenic, non-immunogenic, non-inflammatory and can be used to deliver small 
molecules, proteins, peptides or nucleic acids [14-15]. In addition, the use of nanoparticles 
in drug delivery has many advantages over the use of other nanosystems, such as 
liposomes: higher encapsulation efficiencies, higher stability in physiological conditions 
and improvement of the bioavailability of the drug. Furthermore, the simplicity and low 
cost of the preparation processes make them a highly attractive drug delivery system [16]. 
1.3. Preparation of polymeric nanoparticles 
1.3.1. Polymers used in nanoparticles preparation 
The polymeric composition of the nanoparticles, including their hydrophobicity, surface 
charge, biocompatibility and biodegradation profile, should be taken into consideration 
when preparing nanoparticles for drug delivery purposes. Different polymers, either 
natural or synthetic, can be used in the preparation of biodegradable polymeric 
nanoparticles. The natural polymers commonly used in nanoparticles preparation are 
albumin, gelatin and chitosan [12]. The use of these polymers has several advantages 
including their low cost, biocompatibility with both biological systems and drugs and 
aqueous solubility. However, their use could be limited by the presence of contaminants, 
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the variability from batch to batch, their low hydrophobicity that make them inappropriate 
for the encapsulation of lipophilic drugs, and by the fact that they promote a short duration 
release of the drug [12, 15]. Synthetic polymers are widely used in the preparation of 
nanoparticles as a result of their reproducible manufacture and stability. Furthermore, they 
promote a sustained release of the encapsulated drug for a period of days to several 
weeks [15]. Their limited solubility in aqueous solutions and the need to use surfactants to 
form stable nanoparticle suspensions are some of the drawbacks in the use of this type of 
polymers [17]. Depending on the application of the nanoparticles and to favor a better 
performance, the molecular weight, copolymer composition and degradation rate could be 
changed. Moreover to allow a more precise drug release to target places within the body 
the nanoparticles can be designed with additional properties, like thermo- or pH-sensitivity 
[18]. The most extensively used and studied synthetic polymers for drug delivery are PLA, 
poly(glycolic acid) (PGA) and their copolymers with different ratios of lactic and glycolic 
acid (PLGA) [19-20]. The latter was selected for the studies conducted for this master 
thesis and will be detailed on section 1.3.1.1. Since they are polyesters in nature, and as a 
result of the presence of ester linkages in their backbones, these polymers suffer an 
hydrolysis upon implantation into the body, with the consequent formation of products that 
are easily metabolized in the Krebs cycle and eliminated as carbon dioxide and water [12, 
21]. 
Poly-ɛ-caprolactone (PCL) is a biodegradable, non-toxic and synthetic polymer also used 
in nanoparticle preparation. Since it has a slow degradation rate in comparison with PLA 
and PLGA their use is more adequate for long-term drug delivery [12]. Other synthetic 
polymer used is the poly(alkylcyanoacrylate) (PACA) whose properties can be controlled 
by the side chains introduced, being that the longer the side-chains the longer the half-life 
of the nanoparticles [12]. 
1.3.1.1. Poly( lactic-co-glycolic acid) (PLGA) 
PLGA has generated a huge interest on the development of nanocarriers due to its 
excellent biocompatibility, biodegradability and mechanical strength. This polymer is 
degraded in the body by hydrolytic cleavage of ester linkage with the production of two 
metabolite monomers, lactic acid and glycolic acid that are effectively metabolized in the 
body through the Krebs cycle (Fig.2) [12, 21-22]. 
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Figure 2 – Hydrolysis of PLGA nanoparticles. Adapted from [21]. 
Several factors influence the degradation of PLGA, including the method of preparation, 
the type of encapsulated drugs, intrinsic properties (molecular weight and copolymer 
composition), physicochemical parameters (pH, temperature and ionic strength) and site 
of implantation. The degradation time can go from months to years being that will be 
shorter for polymers with low molecular weight and composed by copolymers with higher 
glycolide content [23]. The degradation of PLGA nanoparticles can occur by two 
mechanisms, bulk erosion or surface erosion (Fig.3). The bulk erosion that is the main 
degradation pathway comprises three phases. Initially it is observed a significant decrease 
in the molecular weight of the polymer as a result of a random scission of ester bonds, 
that is followed by the formation of soluble monomeric and oligomeric products, being that 
the latter’s in the final phase originate more soluble monomeric products, thus favoring the 
complete degradation of the polymer [22]. 
 
 
Figure 3 – Degradation mechanisms of PLGA nanoparticles (A) bulk erosion and (B) surface erosion. 
Adapted from [23]. 
PLGA nanoparticles are internalized mainly through clathrin-mediated endocytosis and 
have a mechanism that allow them to escape the endo-lysosomes and enter the 
cytoplasm in a short period of time (Fig.4), which is extremely advantageous for the use of 
this nanoparticles as cytoplasmic delivery systems [24]. The mechanism responsible for 
the endo-lysosomal escape of the nanoparticles is the surface charge reversal of 
nanoparticles as a result of the acidic pH of these compartments [15, 25]. 
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Figure 4 – Schematic representation of endo-lysosomal escape mechanism. Adapted from [25]. 
The use of PLGA in different drug delivery systems and its application at clinical level was 
approved by US Food and Drug Administration and European Medicine Agency [13, 19]. 
As a result, several drugs used in the treatment of different diseases were successfully 
encapsulated into PLGA microparticles and commercialized in the market [26]. 
1.3.2. Methods used in the preparation of polymeric nanoparticles 
Different methods for the preparation of polymeric nanoparticles are currently available 
and to choose the most appropriate is necessary to take into account the type of polymer, 
the drug to be encapsulated and, the intended use of the nanoformulation. In the 
conventionally used methods, namely emulsification solvent evaporation, 
nanoprecipitation, the method used in this work and that is described in more detail in 
section 1.3.2.1., emulsification solvent diffusion and emulsification reverse salting-out, the 
polymeric nanoparticles were prepared directly from polymers synthesized by 
conventional polymerization techniques, which allows a better control of physicochemical 
and biological properties of the nanoparticles that are formed. Normally, these methods 
include two steps: a first step, that is common to all methods, in which the polymer is 
dissolved in an organic solvent and then emulsified in an aqueous phase, and a second 
step in which the nanoparticles are formed by the evaporation of the organic solvent [12, 
23, 27]. In other methods, such as interfacial poly-condensation, polymeric nanoparticles 
were prepared by the polymerization of the monomers in an emulsion or micelle system 
[12, 27]. 
1.3.2.1. Nanoprecipitation or solvent displacement method 
The nanoprecipitation method (or solvent displacement method), developed by Fessi et al. 
[5] is a simple method in which the nanoparticles are prepared in only one-step. Briefly, 
the polymer and the drug are dissolved in a volatile organic solvent, that is also miscible in 
water (e.g. acetone), and then added dropwise to an aqueous phase that normally has a 
stabilizing agent (e.g. polyvinyl alcohol (PVA)) under magnetic stirring. The rapid 
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formation of the nanoparticles and the drug entrapment are favored by the diffusion of the 
organic solvent to the aqueous phase, being that the organic solvent is then removed by 
slow evaporation. The produced nanoparticles usually have a small size (100-300 nm) 
and a narrow unimodal distribution. The application of this method in the preparation of 
polymeric nanoparticles has some advantages, including the fact of do not involve 
aggressive steps, like sonication, high temperatures and extended stirring rates, 
surfactants are not always needed and the organic solvents normally used are not toxic. 
However, one of the major problems of this technique is the low encapsulation efficiency 
of hydrophilic drugs, since they tend to diffuse into the aqueous phase [23, 28]. 
1.3.3. Nanoparticles characterization 
The capability of nanoparticles to effectively target organs and tissues are influenced by 
morphological characteristics, particle size, surface charge and chemistry, and efficiency 
with which the drug is encapsulated and released. Thus, their use as drug delivery 
systems implies that a systematic characterization is made, in order to verify if their 
properties are the most suitable for pharmaceutical applications. 
1.3.3.1. Morphology 
Morphology of nanoparticles could be readily assessed by imaging techniques like 
scanning electron microscopy [10] used mostly for surface characterization (shape, 
distribution and aggregation), transmission electron microscopy (TEM) [29] used for 
shape, aggregation and internal details and, atomic force microscopy (AFM) [29] used 
mostly for size and morphology. 
1.3.3.2. Size and polidispersity index  
Size is a very important parameter in the characterization of nanoparticles that will be 
used as drug delivery systems, not only because it will influence the release profile and 
degradation rate of the nanoformulations, but also because it will determines their uptake 
by the cells of the mononuclear phagocytic system (MPS) and their biodistribution [30]. 
Although different techniques based on different physical principles can be used to 
measure nanoparticles size, the one that is widely used is dynamic light scattering (DLS), 
also called photon correlation spectroscopy. DLS measures the hydrodynamic diameter 
and is based on the dispersion of light caused by the Brownian motion of the particles, 
which is the random movement of particles due to the bombardment by the solvent 
molecules that surround them. In this technique, the calculation model assumes that all 
particles have a spherical shape, thus if some aggregates are present in the suspension 
the mean size will increase significantly. To have a more accurate measure several 
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parameters such as viscosity, pH, temperature and refractive index of the suspension 
medium should be previously known [30]. DLS also give us an idea of the size distribution 
through the polidispersity index (PDI). Size distributions can be monomodal (one 
population) or plurimodal (several populations) and monodisperse (narrow distribution) or 
polydisperse (broad distribution) (Fig.5). Assuming that the PDI values are in a range from 
0 to 1, values below 0.1 are normally associated to populations with a narrow size 
distribution [30]. 
 
 
Figure 5 – Representation of the curves obtained for two nanoparticles batches of a monodisperse and 
polydisperse population after analysis by DLS. Adapted from [30]. 
Other techniques like TEM, AFM, analytical ultracentrigutation, capillary electrophoresis, 
etc, can be used for size determination although their high cost, difficulty to perform and 
the time consumed make their use slightly disadvantageous [30]. 
1.3.3.3. Surface properties 
Zeta potential corresponds to the overall charge that the particles acquire in a particular 
medium, being an important parameter in the characterization of nanoparticles since it will 
determine if they will cluster in blood circulation or interact with oppositely charged cells 
membrane [31]. Nanoparticles in a liquid suspension are surrounded by a liquid layer 
composed by two parts: an inner layer (Stern layer) where the ions are strongly bound to 
each other and with nanoparticles and an outer (diffuse) layer where they are not so firmly 
bound. Within the diffuse layer exists an imaginary boundary, in which ions and particles 
form a stable entity [32]. The potential formed at this boundary surface is designated zeta 
potential and its determination is achieved through the monitoring of the mobility of 
charged particles by application of an electrical potential [16]. Zeta potential give us 
information on the stability of the particles in suspension, being that its value may be 
positive or negative depending on the nature of the polymer used and the occurrence or 
not of a surface modification. If the particles in a suspension have a high negative or 
positive value the tendency is to repel each other, however when the value is close to 
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zero the particles tend to aggregate. In general, if the zeta potential is above +30 mV or 
below -30 mV the particle suspension is considered stable [16, 32]. 
The chemical characterization analysis is important mostly in the cases where a surface 
modification was made, and the methods usually used include Fourier transformed 
infrared spectroscopy (FTIR) [29], nuclear magnetic resonance [33] and X-ray 
photoelectron spectroscopy [34]. 
The determination of the hydrophobicity/ hydrophilicity of nanoparticles is also an 
important parameter in the characterization of nanoparticles, since it will determines the 
distribution of nanoparticles in the body after administration. This parameter could be 
determined by hydrophobic interaction chromatography [35]. 
1.3.3.4. Encapsulation efficiency and drug release profile 
When a drug is entrapped into the nanoparticles two parameters should be taken into 
consideration: encapsulation efficiency (E.E.) that corresponds to the percentage of drug 
retained in the nanoparticle matrix relatively to the total amount of drug initially used in the 
preparation process; and, drug loading which is the theoretical percentage of loaded 
amount of drug relatively to the total amount of polymer used in the preparation process 
[36]. Ideally, nanoparticles should have high E.E. and a high drug loading in order to 
reduce the quantity of nanoformulation required for administration. Precise determination 
of drug loading is not easy because nanoparticles are colloidal systems and requires a 
previous separation of nanoparticles from non- encapsulated drug, normally by 
ultracentrifugation [21]. To determine E.E. usually a drug extraction is made through the 
dissolution of the nanoparticles in an organic solvent (e.g. acetonitrile). Then the drug 
concentration in the solution can be measured by chromatographic (ultra-performance 
liquid chromatography (UPLC) [37], high-performance liquid chromatography (HPLC) [29]) 
or spectroscopic techniques (fluorescence [38] or ultraviolet spectroscopy [36]). Instead it 
can be determined the quantity of non-encapsulated drug that remains in the aqueous 
phase after preparation and recuperation of nanoparticles being that the value of E.E. is 
calculated as the difference between the amount of drug added to the nanoparticles 
solution and the quantity of non-entrapped drug that remain in the aqueous phase [39-40]. 
The in vitro drug release profile is also an important parameter because of the application 
of nanoparticles in sustained drug delivery. Depending on the type of polymer, on the 
preparation method, on the loading efficiency and on the size of nanoparticles, the drug 
release can occur by four mechanisms: desorption from the surface, diffusion through 
water-filled pores, diffusion through the polymer matrix or as result of polymer dissolution, 
being that in most cases a combination of the erosion and diffusion processes can occur 
[12-13, 41]. In the case of most of the PLGA-based drug delivery systems the drug 
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release follows a biphasic pattern with an initial burst of release that are mainly controlled 
by mechanisms of diffusion, followed by a more slow and controlled liberation that occurs 
as a result of the polymer degradation [42]. Despite the biphasic pattern is most common 
some authors already demonstrate that some drug delivery systems have a triphasic 
release profile [43-45]. Drug release studies are normally performed in vitro using 
centrifugation [43-44] or dialysis methods [42]. Usually in these methods and in order to 
simulate the biological conditions in which the drug delivery system will act, different 
buffers at different pHs are used and the samples are placed at physiological temperature 
(37⁰C). 
1.4. Modification of surface properties 
One of the major issues in the use of polymeric nanoparticles as drug delivery systems is 
their hydrophobicity. After an intravenous administration, hydrophobic nanoparticles are 
rapidly recognized by the body as foreign and cleaned up from the systemic circulation by 
the MPS, ending up on liver, spleen or lymph nodes [46]. If the goal is to use 
nanoparticles for the treatment of a condition in any of the previous referred organs the 
use of hydrophobic nanoparticles is the better choice, however if a sustained systemic 
circulation is required, in order to increase the probability for the nanoparticles reach their 
target, then the surface of hydrophobic nanoparticles must be modified to avoid the 
occurrence of phagocytosis. The aim of these surface modifications is the production of 
nanoparticles that are not recognized by the MPS, as a result of the hydrophilic nature of 
their surface, which favors a longer circulation and the reduction of nonspecific distribution 
[47-48]. Different hydrophilic polymers such as poly-ethylene-glycol (PEG), poly-vinyl 
pyrrolidone, pluronics (poly-ethylene oxides), poloxamers, vitamin E TPGS, polysorbate 
20, polysorbate 80, polysaccharides (e.g. dextran) and different types of copolymers can 
be used to promote the surface modification of nanoparticles [49]. These polymers can be 
introduced at the surface of nanoparticles using adsorbed or grafted shielding groups 
leading to the formation of a hydrophilic protective layer that repels plasma proteins, being 
that in the case of biodegradable nanoparticles, PEG can be incorporated as copolymers 
[46, 50-51]. PEG is the polymer most widely used for the surface modification of various 
polymeric nanoparticles not only because of its hydrophilic, neutral and flexible chains but 
also as a result of the presence of functional groups that are able to efficiently prevent the 
binding of plasma proteins to hydrophobic nanoparticles [52]. It is described that coating 
of polymeric nanoparticles with PEG decreases significantly the opsonization process of 
the particles and the consequent recognition and uptake by macrophages which result in 
an improvement of the long-term systemic circulation of nanoparticles and, higher uptake 
of drug when compared to non-PEGylated ones [53-55]. 
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1.5. Nanoparticles as drug delivery systems – applications in infections therapy 
The application of polymeric nanoparticles as drug delivery systems in the treatment of 
different diseases has been extensively investigated [56-58]. However, despite these 
formulations have more advantages over the use of other nanocarriers like liposomes and 
microparticles, until now only one polymeric-based formulation has reached the market, 
Abraxame®. This polymeric-based nanocarrier consists of a paclitaxel-loaded albumin 
nanoparticles, able to overcome the major drawbacks associated with the use of 
chemotherapeutic agents and effectively against metastatic breast cancer [59]. In fact, the 
main application of polymeric nanoparticles as drug delivery systems is in cancer therapy. 
The effect of chemotherapy in the treatment of different types of cancer is limited by the 
toxic side effects and multidrug resistance [13]. 
Besides nanoparticles application as drug transporters leading to a sustained and 
controlled release of the drug directed to the target site, these systems are also useful to 
improve imaging techniques that allows, for example, an early diagnosis of tumors [13]. In 
that way, and since that it was already demonstrated that polymeric nanoparticles have 
applications in different areas of medicine, is important to continue research related to the 
use of these nanoparticles in the treatment of different diseases (e.g. cancer, infectious 
diseases, metabolic diseases, auto-immune diseases, etc). 
Another field in which nanoparticles are widely applied includes infectious diseases as a 
result of parasitic (e.g. leishmaniasis and malaria), viral (e.g. human immunodeficiency 
virus (HIV)) and bacterial infections (e.g. chlamydia). The treatment of infectious diseases 
has evolved greatly in the last century as a result of the discover of antibiotics and the 
application of a large program of vaccinations. Even tough, as a result of the development 
of resistances and the side effects that many of the compounds used have, infections are 
still a major public health problem and is urgent try to find alternative therapeutics [60]. So 
in that way polymeric nanoparticles constitute themselves as good alternative to defeat 
some of these drawbacks. An example is the encapsulation of saquinavir in PACA 
nanoparticles, which leads to an increase in the cellular uptake of the drug by HIV-infected 
macrophages and to a reduction in viral activity [56]. 
In metabolic diseases, like diabetes and osteoporosis, since the treatments used are 
based on multiple daily injections of peptides and proteins that could limit the success of 
the therapy, the use of polymeric nanoparticles seems to constitute a promising 
alternative to overcome this problem [57]. 
The treatment of autoimmune diseases is based on the use of immunosuppressive agents 
that will modulate the immune response, being that one of the major problems of these 
compounds is poor bioavailability in the target site. However, some studies already 
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demonstrate that the use of polymeric nanoparticles leads to an improvement of the local 
bioavailability of the immunosuppressive agents [58]. 
1.6. Nanoparticles and targeting of immune system – application in immunotherapy 
Functionalization of nanoparticles through the conjugation of ligands that are specifically 
recognized by surface receptors of target cells may favor the stimulation of the immune 
system. Several studies have demonstrated that the use of these nanoparticles induces 
antigen-presenting cells (APCs) maturation, which is evaluated by the expression of co-
stimulatory molecules and by cytokines production, with the simultaneous activation of    
T-cell responses and breaking of self-tolerance [6-7, 61]. 
The different ligands that are currently used to functionalize nanoparticles and which 
sometimes mimics the ones that exist in the surface of pathogens includes proteins, 
peptides, antibodies, polysaccharides, glycolipids, glycoproteins and lectins [62]. APCs 
(e.g. dendritic cells (DC) and macrophages) are cells of the innate immune system that 
play a major role in connecting innate and adaptive immunity, which is important to favor 
the development of a protective response. These cells express a wide variety of pattern 
recognition receptors (PRRs) in their surface that are involved in the recognition of 
pathogen-associated molecular patterns and is involved in the development of the 
immune response. Some examples of PRRs expressed by these cells are Toll-like 
receptors, nucleotide oligomerization domain-like receptors, scavenger receptors and     
C-type lectin receptors (CLRs) [62]. 
Active targeting of nanoparticles into the endocytic receptors expressed by APCs, such as 
CLRs, is a good strategy to improve their efficiency as drug delivery systems. Among 
CLRs, mannose receptor (MR), which is described in more detail on section 1.6.1, has 
been extensively studied as nanoparticles-target receptor due to its capacity to recognize 
mannosylated conjugates. Hamdy et al. [7] have demonstrated that PLGA nanoparticles 
decorated with mannan (MN), a polymannose isolated from the cell wall of 
Saccharomyces cerevisiae, have a strong binding affinity to MR and enhance antigen-
specific T-cell responses, when compared to non-decorated nanoparticles. In another 
study it was demonstrated that mannose-functionalized polyanhydride nanoparticles 
induce and enhance DC activation by specific interactions with MR [6]. 
In theory, the use of functionalized nanoparticles allows targeting specific cell types of the 
immune system (e.g. macrophages and DCs) and most probably enhance the cellular 
uptake by these cells and induce the activation of mechanisms of innate and adaptive 
immunity as a result of the formation of a “danger signal”. 
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1.6.1. Mannose receptor 
MR, also known as CD206 was identified in the late 1970s as a 175 kDa endocytic 
receptor on rabbit alveolar macrophages involved in the recognition of endogenous 
glycoproteins [63] and sugar chains terminated in D-mannose, L-fucose or N-acetyl 
glucosamine [64-65]. This receptor is a member of the MR family which is a subgroup of 
the C-type lectin superfamily and comprises three additional members: M-type 
phospholipase A2 receptor (PLA2R), DEC-205/gp200-MR6 and Endo180/uPARAP [66]. 
MR is a type I transmembrane receptor composed by an extracellular region containing 
three domains: a cysteine-rich domain that is capable of binding to sulphated sugars 
terminated in SO4
-3-galactose (Gal) or SO4
-3/4-N-acetyl galactosamine (GalNAc), acting as 
a second lectin domain; a fibronectin type II domain that is involved in collagen binding; 
and multiple C-type lectin-like domains (CTLDs) within a single polypeptide backbone 
where occurs the binding of sugars terminated in D-mannose, L-fucose or N-acetyl 
glucosamine. It has also a transmembrane domain and a short cytoplasmatic tail that 
contain motifs that mediate receptor internalization and recycling (Fig. 6) [66-67]. Although 
the four members of MR family share structural similarities they differ in the number of 
CTLDs, being that MR, PLA2R and Endo180 have eight and DEC205 has ten. They have 
also a different range of functions, for example, MR has an important role in the innate 
and adaptive immunity, PLA2R is involved in the internalization of soluble PLA2 enzymes, 
DEC-205 internalize antigens for presentation to T cells and Endo180 is involved in the 
extracellular matrix remodeling [66]. 
 
 
 
 
 
 
 
 
 
 
Figure 6 – MR structure – extracellular domains include cisteine-rich domain (red), fibronectin type II domain 
(orange) and eight CTLDs (green). Among the CTLDs, CTLD4 is shown in dark green, since it is the main 
responsible for sugar binding. Adapted from [67]. 
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1.6.1.1. MR expression 
Although the MR was originally termed as macrophage MR its expression is not restricted 
to tissue macrophages. Is now known that it is also expressed on immature murine [68] 
and human [69-70] monocyte-derived DCs, lymphatic and hepatic endothelial cells [71], 
tracheal smooth muscle cells [72], retinal pigment ephitelium [73] and kidney mesangial 
cells [71]. MR expression is modulated by different factors such as cytokines [74-77], 
immunoglobulin receptors [78] and, pathogens and their products [79], which suggest that 
its expression is dependent on the functional state of the cell. Studies of the role of 
cytokines in the regulation of MR expression demonstrate that interleukin (IL) -4 [74],     
IL-13 [75] and IL-10 [76] increase the expression of receptor in macrophages, which 
contrasts to the effect induced by interferon-gamma (IFN-ɣ) that stimulates the activation 
of macrophages and down-regulate the MR expression [77]. It was also demonstrated that 
other agents such as dexamethasone [80], prostaglandin E [81] and                            
1,25-dihydroxyvitamin D3 [82] also promote an increase in MR expression. 
1.6.1.2. MR as an endocytic receptor 
MR is constitutively internalized into early endosomes and sent back to the plasma 
membrane even in the absence of any ligand. At steady state 10-30% of MR are found at 
the cell surface and the remaining ones (70-90%) have an intracellular localization [66]. 
The internalization and deliver of MR into endosomal compartment is possible due to the 
presence of motifs in their cytoplasmic domain that are capable of interact with the 
components of clathrin-mediated endocytic machinery [66]. Clathrin-mediated endocytosis 
is a mechanism mediated by small intracellular vesicles (<0.2 µm) in which a wide variety 
of extracellular components are internalized. Briefly, MR is recruited into clathrin-coated 
pits through motifs present in their cytoplasmatic domain and is automatically internalized 
into early endosomes. In these compartment receptors are targeted to be recycled and to 
go back to the plasma membrane or delivered into late endosomes, which are 
characterized by abundant intravesicular membranes and the presence of active 
lysosomal hydrolases. When they achieve lysosomes, the last compartment of the 
endocytic pathway, the final degradation of internalized cargo occurs as a result of acidic 
pH and high content of active lysosomal hydrolases in this compartment (Fig.7) [66]. 
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Figure 7 – Schematic representation of the clathrin-mediated endocytosis mechanism. Adapted from [66]. 
The role of MR in phagocytosis is still unclear, and the existent data in the literature is 
contradictory. Some authors have demonstrated that MR can function as a professional 
phagocytic receptor although they do not know what the mechanism behind this process 
[67, 83]. Other authors have shown that MR does not act as a phagocytic receptor and 
consider that this receptor per se is not able to mediate phagocytosis, proposing that it 
requires a partner to trigger phagocytosis, which means that although MR binds to 
particles that have terminal mannose residues then it need to recruit a phagocytic receptor 
to drive the phagocytic machinery [84]. 
1.6.1.3. Role of MR in immunity 
MR has an important role in innate immunity that is the first line of defense of an 
organism. In this type of immunity macrophages have an important function since they are 
one of the first cells to arrive at the site of infection and are the main responsible for the 
uptake and degradation of foreign organisms [66]. MR is widely expressed on 
macrophages and act as a PRR since it has highly conserved CTLDs that binds, in a 
calcium-dependent manner, to sugar molecules (e.g. mannose, fucose and N-acetyl 
glucosamine) present on the surface of a wide variety of pathogens, including Candida 
albicans [85], Leishmania donovani [86] and Mycobacterium tuberculosis [87]. Although, it 
is assumed that MR favor the pathogen uptake and, consequently degradation by 
macrophages, in literature there are only a few examples that corroborate this fact [85-87]. 
The absence of signaling motifs in MR cytoplasmatic domain suggest that the clearance 
promoted by this receptor does not lead to cell activation or production of                      
pro-inflammatory cytokines, however several studies suggest that although the receptor 
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appears to require the assistance of other receptors, is capable to trigger a signaling 
cascade [88-90]. Shibata et al. have demonstrated that the use of chitin and mannose-
coated beads stimulate the production of tumor necrosis factor-alpha (TNF-α), IFN-ɣ and 
IL-12 by murine spleen cells, while non-coated beads did not induce any change in 
cytokine production [90]. 
Some evidences suggest that MR may be important in antigen recognition and processing 
and, the fact of this receptor be abundantly expressed on DCs, which are the main APCs 
in the organism, reinforces the idea that this receptor mediates the antigen-internalization 
mechanism in these cells. Studies in which were demonstrated that mannosylation of 
bovine serum albumin leads to an increased internalization and presentation of this 
antigen to T cells [91-92], corroborates this assumption. 
 
1.7. Leishmania parasite 
1.7.1. History and taxonomy 
William Leishman and Charles Donovan were the first ones to describe, separately but 
simultaneously in 1903, the protozoan parasite actually known as Leishmania donovani in 
the spleen from patients in India suffering from a life-threatening disease nowadays 
known as visceral leishmaniasis (VL) [93-94]. 
Leishmania spp. is a diverse group of organisms that belongs to the order 
Kinetoplastidae, characterized by the presence of a kinetoplast in their members, and to 
Trypanosomatidae family. The Leishmania genus can be divided into two subgenera, 
Leishmania (Leishmania) spp. and Leishmania (Viannia) spp. (Table 1). These parasites 
are the causative agents of leishmaniasis, existing more than 20 species that can promote 
the development of the disease. They are transmitted by the bite of female sandflies, 
belonging to the genus Phlebotomus in the Old World and Lutzomyia in the New World 
[93, 95]. 
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Table 1  - Human pathogenic Leishmania species, clinical manifestations and geographical distribution [95] 
Species Clinical manifestation Geographical distribution 
Old World, subgenus Leishmania   
L. donovani VL; PKDL Africa, India 
L. infantum VL; CL (rare) Mediterranean, Asia, Sub-
Saharan 
L. tropica CL; VL (rare) Middle East, India, 
Mediterranean 
L.major CL Africa, Middle East, India, China 
L. aethiopica CL; DCL  East Africa 
New World, subgenus Leishmania   
L. chagasi * VL; CL (rare) Latin America 
L. mexicana CL; DCL Central America 
L. amazonensis CL; DCL; MCL; VL (rare) Central and South America 
New World, subgenus Viannia   
L.braziliensis CL; MCL South America 
L. guyanensis CL South America 
L. panamensis CL South America 
L. peruviana CL Central and South America 
VL, visceral leishmaniasis; PKDL, post kala-azar dermal leishmaniasis; CL, cutaneous leishmaniasis; DCL, diffuse 
cutaneous leishmaniasis; MCL, mucocutaneous leishmaniasis. 
*There are growing evidences suggesting that L. infantum and L. chagasi are the same species [96] 
1.7.2. Life cycle 
Leishmania parasites have a digenetic life cycle, which means that they can successfully 
develop in two hosts, vertebrate (humans, dogs and other mammals) and invertebrate 
(insects (e.g. sand fly)). In the life cycle two main morphological forms of the parasite can 
be distinguished: an extracellular and motile promastigote form found within the sand-fly 
and an intracellular, non-motile and proliferative amastigote form that lives in a variety of 
mammalian cells, mostly within professional phagocytes such as macrophages [93, 97]. 
Promastigotes (Fig. 8A) are the elongated (10-20 µm), motile and flagellated form of the 
parasite, that are found within the alimentary tract of the sand fly where progress through 
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a differentiation process, known as metacyclogenesis, to ultimately form the non-dividing 
and highly infectious form of the parasite, the metacyclic form [93, 97]. 
Amastigotes (Fig. 8B) are the round or oval, non-motile and aflagellated form of the 
parasite (3-7 µm in diameter) and are able to survive and replicate inside the 
phagolysosome of the host mononuclear phagocytes. Contrarily to other pathogens 
Leishmania amastigotes survive and divides in the adverse conditions of phagolysosome 
(acidic pH, presence of hydrolytic enzymes and reactive species of oxygen and nitrogen) 
[93, 97]. 
 
 
 
 
 
Figure 8 – Leishmania morphological forms: (A) Leishmania promastigotes (Adapted from [98]) ; (B) 
Leishmania intracelular amastigotes stained with Giemsa (Adapted from [99]) 
 
Infection of the mammalian host is initiated when an infected Phlebotominae female sand 
fly, during blood feeding, inoculate metacyclic promastigotes together with various salivary 
components in dermis. Once in the vertebrate host the metacyclic promastigotes are 
rapidly internalized by the resident dermal or recruited phagocytic cells (e.g. neutrophils, 
macrophages and DCs), either directly or indirectly based on Trojan Horse model, 
according to which neutrophils are initially recruited to the sand fly bite and infected by 
Leishmania promastigotes suffering, shortly after infection, spontaneous apoptosis, being 
that the clearance by macrophages allows the indirect entry of the parasites into their final 
host cells [100]. Promastigotes are targeted to phagosomes in the macrophages that fuse 
with lysosomes forming a phagolysosome, within which they differentiate to the 
amastigote form. The change in temperature (from 25⁰C in sandfly to 37⁰C in the host) 
and the acidic environment (pH around 5) in the phagolysosome induces the 
differentiation of the promastigote form into the amastigote form. Then amastigotes 
proliferate by binary cell division within the host cells, which leads to their lysis when too 
many amastigotes are present, allowing the infection of other macrophages as wells as 
other phagocytic cells (e.g. DCs) and non-phagocytic cells (e.g. fibroblasts). When a sand 
fly ingests infected phagocytes with the blood meal, initiates the insect stage of the 
parasite life cycle. In this stage, after the ingestion of infected macrophages, the 
amastigotes are converted in flagellated and slight motile procyclic promastigotes that 
multiply by binary fission. On a later stage of metacyclogenesis Leishmania procyclic 
promastigotes differentiate into infective, non-dividing metacyclic promastigotes that 
A B 
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migrates to the sand fly salivary glands and are able to infect a mammalian host, mainly 
due to high expression of virulence factors like, lipophosphoglycan and glycoprotein 63 
(Fig.9) [93, 97, 101-102]. 
 
 
Figure 9 - Leishmania life cycle. Adapted from [97] 
1.8. Leishmaniasis 
Leishmaniasis is a neglected tropical disease that is caused by infection with one of 
several different species of protozoan parasites of the genus Leishmania. (Table 1). This 
is a poverty-related disease and its high prevalence is normally associated with 
malnutrition, poor housing, illiteracy, weakness of the immune system, lack of resources 
and environmental changes. 
1.8.1. Epidemiology and geographical distribution 
World Health Organization (WHO) has classified leishmaniasis as an emerging and 
uncontrolled disease, which causes 70,000 deaths each year. Currently, this disease is 
considered to be endemic in 88 countries (16 developed countries and 72 developing 
countries) on four continents. Leishmaniasis is mainly distributed in tropical and 
subtropical regions that include, Africa, Middle East, Southweast Asia, Southern Europe 
and, Central and South America (Fig.10), which is in agreement with the fact that these 
regions have a high prevalence of sand fly vectors [103]. It is estimated that about        
350 million people are living at risk of developing one of the many forms of the disease 
and there are 12 million people currently infected worldwide. There are 2 million new 
cases of leishmaniasis per year, although there are reasons to believe that the number is 
increasing as a result of man-made environmental changes that promote an increased 
humane exposure to the sand fly vector and migration [94, 104]. 
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Figure 10 - Geographical distribution of reported cases of Leishmania infection and Leishmania/HIV-1 co-
infection from 1990 to 1998. Adapted from [105]. 
 
Leishmaniasis has emerged as one of the main opportunistic infections that affect       
HIV-infected individuals, being the visceral form the one that most contribute to co-
infection. According to the WHO, until now 35 countries around the world have reported 
cases of Leishmania/HIV-1 co-infection (Fig. 10). The increment in the number of cases of 
co-infection is a result of the increase overlap in the geographical areas with high risk of 
HIV-1 infection (urban areas) and leishmaniasis (rural areas). Leishmania and HIV-1 act 
synergistically on the immune system weakening it so that lead to death of the individual 
[105]. 
1.8.2. Clinical manifestations 
Leishmaniasis has a large spectrum of clinical manifestations that goes from contained 
cutaneous ulcers to fatal, if left untreated, visceral disease. The clinical presentation of the 
disease depends on the causative agents and on the host immune response. The 
different clinical manifestations of leishmaniasis, as well as the fact that this disease could 
be caused by more than 20 protozoan species transmitted by approximately 30 different 
species of phlebotomine sandflies, reflects its diversity and complexity [106]. 
Leishmaniasis consists of three main clinical forms: cutaneous leishmaniasis, 
mucocutaneous leishmaniasis and visceral leishmaniasis. 
 
Leishmania infection 
Leishmania/HIV—1 co-infection 
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1.8.2.1. Cutaneous leishmaniasis 
Cutaneous leishmaniasis (CL) is caused by a number of species from both subgenera 
(Leishmania and Viannia) belonging to Old and New World (Table 1). Patients with this 
disease generally present one or several ulcer(s) or nodule(s) in the exposed areas of the 
skin, such as the face, arms and legs (Fig.11A). These ulcers normally self-heal in 
immune-competent individuals, leaving disfiguring scars, being that the time necessary to 
complete healing will depend on the immune status of the host [93, 107-108]. Despite CL 
be endemic in more than 70 countries worldwide, 90% of cases occur in Afghanistan, 
Brazil, Iran, Peru, Saudi Arabia and Syria [109-110]. 
Diffuse cutaneous leishmaniasis (DCL), a more severe and chronic form of CL, is caused 
by L. aethiopica, L. mexicana and L. amazonensis and is characterized by the spread of 
the primary lesions to multiple areas of the skin [108]. 
1.8.2.2. Mucocutaneous leishmaniasis 
Leishmania brazilienses is responsible for most cases of mucocutaneous leishmaniasis 
(MCL), also known as espundia (Table 1). This disease is characterized by the formation 
of progressively destructive ulcerations in the mucosal membranes of the nasal and 
buccal cavities, which then spread to the pharynx and larynx (Fig. 11B). The lesions don’t 
heal spontaneously and are very difficult to treat. Since this disease can develop as a 
result of an inadequate treatment of a cutaneous infection which can result in the 
appearance of mucosal metastasis in nasopharynx, it is recommended that CL is promptly 
treated [93, 107-108]. 90% of MCL occurs in Bolívia, Brazil and Peru [110]. 
1.8.2.3. Visceral leishmaniasis 
Visceral leishmaniasis (VL), also known as kala-azar, is a systemic disease that is fatal 
when left untreated and is caused by species of the Leishmania donovani complex, 
namely L. donovani and L. infantum (Old World) and L. chagasi (New World) (Table 1). 
The causative agents could have two ways of transmission, zoonotic (L. infantum and     
L. chagasi), which means that is transmitted from animal to vector to human or 
anthroponotic (L. donovani), which means that is transmitted from human to vector to 
human. The development of the disease is a consequence of the dissemination of VL 
causing species to internal organs such as the liver, spleen and bone marrow, which 
results in the appearance of different symptoms of persistent systemic infection, including 
prolonged fever, anemia, loss of appetite and weight and polyclonal 
hypergammaglobulinaemia and, symptoms of parasitic invasion of the blood and   
reticulo-endothelial system, like swelling of spleen (splenomegaly), liver (hepatomegaly) 
and lymph nodes (Fig. 11C). Although the infection produces only moderate toxic 
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symptoms, as a result of severe weight loss, anemia and systemic impairment, the patient 
dies if is not conveniently treated. Although patients that recovered from VL have lifelong 
immunity, in some cases the reactivation can occur (e.g. HIV infection) [1, 93, 107-108]. 
Most of the VL cases (90%) occurs in Bangladesh, Brazil, India, Nepal, Sudan and 
Ethiopia [110]. There are 500,000 new cases of VL per year, being that the increased 
incidence of this disease is associated with migration, lack of control measures and      
VL-HIV co-infection. This disease is responsible for more than 50,000 deaths per year 
[107]. 
Post kala-azar dermal leishmaniasis (PKDL) is a complication of VL, frequently observed 
in patients a few months or years after treatment and is characterized by a macular, 
macula-papular or nodular rash in the face and limbs (Fig. 11D). As a result of the high 
number of parasites present in nodular lesions, PKDL patients are more susceptible to 
infections [93, 107-108]. 
 
Figure 11 - Clinical manifestations of leishmaniasis. Patients with (A) cutaneous leishmaniasis, (B) 
mucocutaneous leishmaniasis, (C) visceral leishmaniasis, and (D) post kala-azar dermal leishmaniasis. 
Adapted from [107]. 
1.9. Treatment of leishmaniasis 
Leishmaniasis has higher incidence in less developed countries where, for economic 
reasons, exist serious limitations in diagnosis, disease control and treatment. Since there 
is no commercially available human vaccine against leishmaniasis the control of this 
disease is dependent on drug therapy and vector control. The drugs currently used in the 
treatment of leishmaniasis have severe side effects, are poorly tolerated, induce the 
emergence of resistances, most of them involve a long period of treatment, close medical 
supervision, and are ineffective in situations of disease exacerbation [1-3, 111]. Thus it is 
of great importance to develop new drugs and/or formulations that replace or complement 
the ones that are current available. 
1.9.1. Current treatment options 
1.9.1.1. Pentavalent antimonials 
Pentavalent antimonials, which were developed in 1945, are still the drugs recommended 
by the WHO as first-line of treatments against CL and VL. The compounds from 
A B C D 
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pentavalent antimonial family, namely the commercially available sodium stibogluconate 
(Pentostam®) and meglumine antimoniate (Glucantime®), remain as the main therapy for 
leishmaniasis in most regions with the exception of Bihar State, India, because of the high 
prevalence of resistance (more than 60%) and, in Europe, not related to drug resistance, 
but because of the availability of highly effective forms of treatment. [3, 112]. Although the 
compound is used for a long time in the treatment of leishmaniasis their mechanism of 
action is not yet completely understood. Antimonials have several disadvantages including 
the long duration of the treatment, the requirement of a parenteral administration and 
consequently a close medical supervision, the toxic effects (nausea, abdominal pain, 
chemical pancreatitis and cardiotoxicity) and the emergence of resistances [3]. 
1.9.1.2. Pentamidine 
Pentamidine (isethionate or methansulphonate) is an aromatic diamine, previously used, 
in areas of antimonial resistance, as a second line treatment for VL, however as a result of 
its toxic side effects (hypoglycemia, nephrotoxicity, hypotension, etc) and emergence of 
resistant strains, the use of this drug, in India, for the treatment of VL was abolished [3, 
113]. However for CL was demonstrated that the low doses of pentamidine and a short 
course period of treatment promotes a high cure rate, making this drug a good alternative 
in cases of CL [114]. 
1.9.1.3. Amphotericin B  
Amphotericin B (AmB) is a polyene antifungal antibiotic agent, discovered in 1956, from a 
bacterium of genus Streptomyces, widely used to treat systemic fungal infections. AmB 
have a high affinity for ergosterol that is the main component of the cell membrane of 
fungi and Leishmania parasite. The antileishmanial activity of this compound is due to its 
interaction with ergosterol. Although in a lesser extent AmB also interacts with cholesterol 
of host macrophages inhibiting the bind of the parasite to cells, being that at higher 
concentrations (<0.1M) it induces the formation of aqueous pores in leishmanial cell 
membranes leading to parasite death [1, 111]. AmB constitutes a second line of 
treatment, except in areas of antimonial resistance, like Bihar State in India, where it is the 
drug of choice. The major drawbacks associated with the use of AmB are the higher 
costs, the limited availability in some areas, difficulties associated with the administration 
(slow infusions), prolonged duration of therapy (up to 30 days) and the severe side effects 
(fever, bone pain, chills, hypokalemia, renal impairment and anemia) [1, 3-4]. To 
overcome some of these issues, especially the high toxicity, three effective lipid-
associated formulations of this compound, unilamellar liposomal formulation 
(AmBisome®), colloidal dispersion (Amphocil) and lipid complex (Abelcet), were 
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implemented. These lipid formulations not only retain the fungal activity of AmB but are 
also more effective and well tolerated since their physicochemical properties favors their 
uptake by the reticuloendothelial cells in the liver, spleen and bone-marrow that are the 
main targets of VL [1, 3, 111]. They have been evaluated in clinical trials for VL and CL 
and the results showed that AmBisome® and Amphocil are more effective than Abelcet in 
the treatment of VL and the reduction of the size of the lesions in CL is more significant 
with the use of AmBisome® [115]. Despite its efficacy the high costs limits its use in less 
developed countries. Some studies have demonstrated that the effectiveness of AmB 
treatment is dependent of the patient immunity status and that successive relapse could 
favor the appearing of clinical resistances against the compound. Thus, although until now 
doesn’t exist any report of clinical resistance against AmB, these studies supports the 
possibility of their development [116-117]. 
1.9.1.4. Miltefosine 
Miltefosine (hexadecylphosphocholine) is a membrane activating alkyl phospholipid that 
was originally developed as an antineoplastic agent. After clinical studies, it was approved 
as ImpavidoTM and become the first commercial available oral drug for the treatment of 
VL. This drug has many advantages including its high efficiency, low cost, the short 
course of the treatment, reduced side effects and the fact of be orally administered and 
well tolerated allowing it to be made an ambulatory treatment without the need of a close 
monitoring. However miltefosine has some disadvantages related to its teratogenicity, 
which limit its use in women that are pregnant or in reproductive age and, to its long    
half-life (≈7 days) that increases the possibility of development of resistances [113, 118]. 
1.9.1.5. Paramomycin 
Paramomycin (aminosidine) is an aminoglycosidic antibiotic with antileishmanial activity. 
This antibiotic can be used for the treatment of both VL and CL, however the poor oral 
absorption led to the development of parenteral and topical formulations, for VL and CL, 
respectively [119]. The results of phase III clinical trials conducted in Bihar, India revealed 
that this drug have a high efficacy, not inferior to AmB, and safety since treated patients 
do not present nephrotoxicity, and only a small percentage present damage of the inner 
ear and a significant increase in hepatic transaminases [120]. Furthermore, paramomycin 
have other advantages namely the fact that it is active against different pathogens, 
including bacteria, the short duration time of its administration and its low cost in 
comparison to the other treatments currently available for leishmaniasis [107]. 
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1.9.2. Combined therapy 
The implementation of a combined therapy aims to increase treatment efficacy, prevent 
the development of drug resistances, reduce treatment duration and if possible, the 
treatment cost [121]. It was demonstrated that the use of a combination therapy with 
sodium stibogluconate and paramomycin in the treatment of VL was more safe and 
effective than the therapy with sodium stibogluconate alone. These clinical studies 
conducted in India and East Africa also showed that combined therapy allows a reduction 
in the duration of the treatment, from 30 to 17 days [122]. A combination therapy including 
liposomal AmB and miltefosine is being currently studied in India [107]. 
1.9.3. New formulations in the treatment of leishmaniasis 
Leishmania spp. are characterized by its ability to survive and replicate inside the host 
phagocytes and by its capacity to disseminate for different locations, which constitutes a 
great challenge to drug discovery and delivery since the intracellular localization protects 
them against the action of drugs that are not able to diffuse readily into cells. The use of 
some drug carriers, including emulsions, liposomes and nanoparticles is of great interest, 
because it allows the selective distribution to phagocytic cells, prevent the action of drugs 
in uninfected tissues and consequently reduce the toxicity and increase the efficiency of 
the antileishmanial compounds. 
Liposomes and polymeric nanoparticles were already tested as drug delivery systems for 
antileishmanial compounds showing a great potential to improve the efficacy and 
tolerability of these compounds [123]. Liposomes are widely used as drug carriers since 
they are capable to entrap hydrophilic and hydrophobic drugs reducing its toxicity, are 
highly versatile, their surface can be easily modified and when administered intravenously 
are rapidly captured by the phagocytic cells present on liver and spleen that are the main 
target organs in VL [62]. One of the first applications of liposomes was the treatment of 
leishmanial infections [124]. Although it has been demonstrated that the encapsulation of 
some antileishmanial drugs, namely pentavalent antimonials and miltefosine, in liposomes 
increases its effectiveness in the treatment of leishmaniasis [125-127], the most 
successful example is AmBisome®, the only liposomal product approved and 
commercially available for treatment of VL. The AmBisome® has the advantage of 
reducing the toxicity associated with free drug. In fact, its small size (<100 nm) prevents 
its immediately uptake by macrophages of liver and spleen allowing their circulation in the 
blood to reach other infected tissues, like lungs, kidney and brain. These formulations also 
have the advantage of killing microorganisms that were not phagocytised. Nowadays, 
AmBisome® is considered an excellent treatment option not only for VL but also for fungal 
infections, however the high costs associated with the use of this formulation limits its 
36 
 
application in developing countries. Another liposomal formulation of AmB (Abelcet®) is 
commercially available, however it is less effective when compared with 
AmBisome®[128]. The most promising strategy to overcome the problems associated with 
the costs of these liposomes-based treatments appears to be the development of 
formulations using polymeric nanoparticles. 
Polymeric nanoparticles can be useful in the treatment of macrophage-mediated 
diseases, like leishmaniasis, since the small size of these formulations favors its efficient 
cross through biological barriers, improved cellular uptake and the delivery of the 
therapeutic agents in infected sites. The main advantage of polymeric nanoparticles when 
compared to liposomes is the ability that they have to withstand physiological stress or 
improved biological stability and possibility of oral delivery [128]. When polymeric 
nanoparticles are used for treatment of leishmaniasis is fundamental to consider the type 
of polymer used because it hydrophobicity will influence the uptake by macrophages, that 
are the main targets in leishmaniasis. Several studies [129-133] demonstrate the efficacy 
of polymeric nanoparticles in the treatment of VL. Primaquine loaded- PACA and PLA 
nanoparticles showed an increase on efficacy and reduced toxicity when compared with 
the free drug. Moreover, unloaded PACA nanoparticles have, per se, an antileishmanial 
activity equivalent to free primaquine, which is not verified in the case of unloaded PLA 
nanoparticles [129-130]. The incorporation of pentamidine in polymethyl methacrylate and 
of AmB in PCL biodegradable nanoparticles improves their antileishmanial activity and 
reduces the side effects of the free compounds [131-132]. The antileishmanial activity of 
2’,6’-Dihydroxy-4’-methoxychalcone, a compound of natural origin, was improved             
≈ 2.3-fold when it is encapsulated in PLA nanoparticles [133]. 
The surface of both liposomes and polymeric nanoparticles can be modified by the use of 
targeting ligands that are recognized by specific receptors presents on phagocytic cells, 
which will direct their internalization and posterior action, at a specific cell/ site. In a recent 
study the use of AmB-loaded mannose-coated liposomes was explored for selective 
delivery of drug to macrophages in the treatment of VL and it was demonstrated that 
functionalization of this formulations with mannose leads to a higher uptake in the liver 
and spleen which favors the direct action of the drug in the region where the parasite 
resides, and at the same time prevent the action of drugs in other organs reducing its 
toxicity [134]. In another study the use of functionalized polymeric nanoparticles in the 
treatment of VL was explored [29]. Taking into account that MR are present mainly in the 
surface of macrophages and DCs the authors have prepared AmB-loaded PLGA 
nanoparticles containing the MR specific ligand (mannose). The results showed that the 
functionalization of polymeric nanoparticles with mannose leads to a higher uptake and 
increased antileishmanial activity [29]. 
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II. AIMS 
In the last decades significant progresses were made in understanding the 
immunopathogenesis of leishmaniasis, however until now, no effective and safe treatment 
was discovered. Moreover, currently available drugs for the treatment of this disease are 
associated with emerging resistance and elevated toxicities. In that way it is of great 
importance to develop alternative treatments, like nanotechnology-based drug delivery 
systems, that replace or complement the ones that are current available. Furthermore, it 
has been demonstrated that the efficiency of PLGA-based drug delivery systems in the 
treatment of leishmaniasis could be improved by their functionalization with ligands that 
specifically target MR, a member of CLR family that is highly expressed on APCs, the 
target cells in VL. In that way, the first purpose of the present work was to develop a 
mannosylated nanoparticulate system for efficient delivery of AmB, being that the strategy 
chosen involves: (1) the preparation of unloaded mannose-coated PLGA (M-PLGA) 
nanoparticles by three different techniques physical adsorption (PA), one-step chemical 
reaction (CR1) and two-step chemical reaction (CR2), their biophysical characterization 
and evaluation of their cytotoxicity towards macrophages and intracellular Leishmania 
infantum amastigotes, to determine which of those techniques are more suitable for the 
preparation of nanoparticles; (2) use the developed nanoparticulate system to 
encapsulate AmB and evaluate the in vitro efficacy of the new delivery systems against 
Leishmania –infected macrophages; (3) assessment of the new nanoformulation 
differential uptake by APCs, through ex vivo and in vivo studies, using splenocytes 
isolated from Balb/c mice. 
Functionalization of nanoparticles through the conjugation of ligands that are specifically 
recognized by surface receptors on target cells may favor the stimulation of the immune 
system. Several studies have demonstrated that the use of these nanoparticles induces 
DCs maturation, which is evaluated by the expression of co-stimulatory molecules and by 
cytokines production, with the simultaneous activation of T-cell responses [6-7, 61]. Thus, 
the second purpose of this work was to identify the optimum mannosylated 
nanoformulation for efficient delivery to APCs, using PLGA nanoparticles functionalized 
with three different sugars, mannose (M), mannan (MN) and mannosamine (Ms) and 
evaluate the extent in which these formulations affect the activation status of the cells, as 
well as the type of response that they will modulate in APCs. 
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III. MATERIALS AND METHODS 
3.1. Chemical reagents 
PVA [87-89 % hydrolysed , molecular weight (MW) 13 000 – 23 000 g/mol],                     
D-(+)-mannose (MW 180.16 g/mol), mannan, from Saccharomyces cerevisiae,                
D-mannosamine hydrochloride (MW 215.64 g/mol), N-hydroxysuccinimide (NHS)        
(MW 115.09 g/mol), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (DCC) 
(MW 191.7 g/mol), AmB, from Streptomyces (MW 924.1 g/mol) and fluorescein 
isothiocyanate isomer I (FITC) (MW 389.38 g/mol). All reagents were purchased from 
Sigma-Aldrich (Sintra, Portugal). PLGA (70:30) (MW 10 000 g/mol) was purchased from 
Polysciences, Inc .(Valley Road, Warrington). 
3.2. Preparation of nanoparticles 
3.2.1. Preparation of PLGA nanoparticles loaded with AmB or FITC 
PLGA nanoparticles were prepared by the nanoprecipitation method [5] in the presence of 
a specific amount of AmB or FITC (% drug loading (w/w)). Briefly, a mass of ± 10 mg of 
PLGA was rigorously weighted (Analytical Balance Kern ABS) and dissolved in 
approximately 1 mL of acetone, in a glass tube. To obtain the desired % drug loading 
(mass of compound per mass of polymer) a defined volume of a stock solution of            
10 mg/mL AmB or 50 mg/mL FITC, both in dimethyl sulphoxide (DMSO) was added to the 
previous solution. Then, the formed organic phase was added dropwise to an aqueous 
solution of 1% (w/v) PVA using a 19G syringe. The emulsion was left under magnetic 
stirring for 10 minutes, followed by slow evaporation of the organic solvent using a rotator 
evaporator over-night. After that, the nanoparticles were recovered and washed by 
centrifugation. An initial centrifugation at 5,000 xg for 5 minutes at 20⁰C (Sigma 3K18 
Laboratory Centrifuge; Philip Harris Scientific, Lutterworth, UK) was performed to remove 
larger particle aggregates. The resulting supernatant was recovered and centrifuged at 
20,000 xg for 20 minutes at 20⁰C in order to obtain the nanoparticle sediment that is then 
washed twice, with distilled water, by centrifugation at 20,000 x g for 20 minutes at 20⁰C. 
The final sediment was re-suspended in 2 mL of phosphate-buffered saline (PBS)       
(137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 2.0 mM KH2PO4; pH 7.4) and the 
supernatants obtained from the washing steps (S1, L1 and L2) were stored at 4⁰C for 
quantification of drug encapsulation. Plain (empty) PLGA Nanoparticles were prepared 
using the same procedure without the addition of compound. Nanoparticle suspensions 
were sterilized by exposure to ultraviolet light (20 minutes) and stored at 4⁰C until further 
use. 
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The FITC-loaded PLGA nanoparticles were prepared in aseptic conditions. All reagents, 
glass and plastic equipment’s were sterilized by autoclaving, exposure to ultraviolet light 
or filtration and all the steps involved in the preparation of the nanoparticles (stirring, 
mixing and suspending) were done inside a biosafety cabinet. All FITC-nanoformulations 
were tested for the presence of endotoxin using a kit (CellToxTM, Promega, Madison, 
USA) accordingly to the manufacturer instructions, and were shown to be endotoxin free. 
3.2.2. Mannose incorporation 
Mannose was attached to PLGA nanoparticles (M-PLGA nanoparticles) by three different 
techniques: PA, CR1 andCR2. For PA 20 mg of mannose were added to 10 mg of PLGA 
nanoparticles dispersed in 5 mL acidic PBS (pH 5.0), and the mixture was then stirred at 
room temperature over-night. The PLGA nanoparticles with adsorbed mannose were then 
collected and washed off from soluble mannose by successive centrifugations as 
described on section 3.2.1. In CR1 a mixture of 20 mg of mannose, 153 µg DCC and 
0,459 µg NHS were added to 10 mg of PLGA nanoparticles dispersed in 5 mL acidic PBS 
(pH 5.0) and in CR2, first 10 mg of PLGA dispersed in 5 mL acidic PBS (pH 5.0) were 
incubated with the activators of PLGA carboxyl groups (NHS and DCC), in the same 
quantities that we use for CR1, during 2 hours, followed by the incubation with 20 mg 
mannose over-night. In both types of chemical reaction the excess reagents and soluble 
by-products were washed away at 20,000 xg for 20 minutes at 20⁰C. The final sediment 
was re-suspended in 2 mL of pH7.4 PBS and the supernatants obtained from the washing 
steps (S1, L1 and L2) were stored at 4⁰C for quantification of drug encapsulation. 
Nanoparticle suspensions were sterilized by exposure to ultraviolet light (20 minutes) and 
stored at 4⁰C until further use. 
3.2.3. Mannan and mannosamine incorporation 
In the case of FITC-loaded nanoparticles the coating were made not only with M, but also 
with MN and Ms. These two sugars were attached to PLGA nanoparticles (MN-PLGA and 
Ms-PLGA nanoparticles) by CR1, following the same procedure described on the previous 
section. 
3.3. Characterization of nanoparticles 
3.3.1. Size, polydispersity index and zeta potential 
Size, polydispersity index and zeta potential determinations were performed by dynamic 
light scattering methods using a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) 
with a detection angle of 173⁰. Measurements were made in triplicate at 25⁰C. The 
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samples for dynamic light scattering analysis were prepared by diluting the nanoparticle 
suspension in distilled water to a final concentration of 1 mg/mL in polymer. 
3.3.2. Transmission Electron Microscopy 
The morphology of prepared nanoparticles was determined by TEM (Jeol JEM-1400, 
Tokyo, Japan). About 10 µL of the aqueous dispersion of nanoparticles was placed on 
carbon coated copper grids and after 1 minute excess was removed and the sample 
stained with an aqueous solution of 3% uranyl acetate for 30 seconds. Samples were then 
observed in a microscope at the accelerating voltage of 60 kV. 
3.3.3. Fourier Transform Infrared Spectroscopy 
The molecular structure of uncoated and M-PLGA nanoparticles was confirmed using 
FTIR (Perkin Elmer 2000 FTIR/ RAMAN system, Massachusetts, USA). For FTIR analysis 
the nanoparticles were freeze-dried using 5% trehalose, followed by vacuum dried at 
25⁰C. Then the obtain solid samples were milled with potassium bromide, in a proportion 
of 1:100, to form a very fine powder, that is then compressed within two stainless steel 
disks using hydraulic pressure. After that, the formed film, which should be homogenous 
and transparent in appearance, was removed and used to obtain the FTIR spectrum. 
3.3.4. Lectin Binding Assay 
In order to assess the surface orientation and availability of mannose ligand after 
formation of coated PLGA nanoparticles, an agglutination test was carried out using 
Concanavalin A (ConA) lectin (Sigma Aldrich, Sintra, Portugal) [135]. Briefly, 200 µL of   
M-PLGA nanoparticles were diluted 10 times with PBS pH 7.4 containing 5 mM of calcium 
chloride and 5 mM of magnesium chloride (both from Sigma Aldrich, Sintra, Portugal), 
then ConA was added to a concentration of 25 µg/mL and time-dependent increase in 
turbidity at 550 nm was monitored spectrophotometrically (Sinergy 2, BioTek) for            
90 minutes. 
3.3.5. Quantification of mannose, mannan and mannosamine 
The effect of polymer type and coating method on the incorporation level of the used 
sugars was investigated by indirect quantification using phenol-sulfuric acid reaction. M, 
MN or Ms that are present in larger particle aggregates were extracted using a 
dichloromethane (DCM)/water extraction system. Briefly, 5 mg of aggregates were 
dissolved in 500 µL DCM in an eppendorf tube by vortexing. Then 700 µL of water was 
added and the two phases were mixed thoroughly. The aqueous phase was separated 
and heated in a horizontal lab shaker at 40⁰C to evaporate the remaining DCM, which is 
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followed by a centrifugation at 14,000 xg, for 15 minutes at 20⁰C to remove the insoluble 
fractions. The sugar dissolved in the supernatant previously obtained and in the 
supernatants obtained from the washing steps (S1, L1 and L2) was then quantified by 
phenol-sulfuric acid reaction [136]. In this colorimetric assay, to 50 µL of supernatant in a 
flat 96-well microplate, 150 µL of concentrated sulfuric acid (96%) were rapidly added to 
favor maximum mixing. Immediately after that, we add 30 µL of 5% (w/v) phenol solution 
and then the plate was incubated in a heated static water bath for 5 minutes at 90⁰C to 
favor the color development. The plate was then cooled down at room temperature to stop 
reaction and the absorbance was read at 490 nm in a microplate reader (Sinergy 2, 
BioTek). Linear calibration curves relating sugar concentration and absorbance at 490 nm 
were made in the range of 4.50-0.03 mg/mL and the extent of sugar incorporation in 
nanoparticles was expressed as the amount of mannose, mannan or mannosamine    
(mg/ mg of polymer) and was calculated as: 
                                
m initial solution – m Agregattes     L  L2
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3.3.6. Storage Stability 
Storage condition assays were performed in order to evaluate the stability of empty M-
PLGA nanoparticles, prepared by CR1, at -20⁰C, 4⁰C and 37⁰C. Nanoparticle 
suspensions were divided in aliquots of 100 µL, stored at -20⁰C, 4⁰C and 37⁰C and over a 
period of 8 weeks an aliquot was periodically diluted in distillated water to give a final 
concentration in polymer of 1 mg/mL. This sample was then analyzed for size, 
polydispersity index and zeta potential by dynamic light scattering methods using a 
Zetasizer Nano ZS. 
3.3.7. Encapsulation efficiency 
3.3.7.1. AmB 
E.E. of AmB in uncoated and M- PLGA nanoparticles was determined directly by UPLC 
(Acquity Ultra Performance LCTM, Waters Corp., Milford, MA, USA) using an Ethylene 
Bridged Hybrid C18 column (Acquity UPLC®, Waters) (150 x 2.1 mm, 1.7 µm particle 
size; Waters Corp., Milford, MA, USA) maintained at 20⁰C. The autosampler temperature 
was maintained at 4⁰C. The conditions established for the gradient elution program used 
in the analysis of AmB are shown in Table 2. The mobile phase was comprised of          
(A) 0.1 M ammonium acetate pH 4 and (B) acetonitrile at a flow rate of 0.1 mL/min. The 
injection volume was 10 µL when the full loop mode was selected for sample injection. 
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The detection was performed at a 407 nm wavelength using a photodiode array detector 
with total running time of 6 min. The retention time was found to be 4.3 minutes. Data 
acquisition, data handling and instrument control were performed by MassLynx software 
(Waters Corp., Milford, MA, USA). 
Table 2 – Gradient elution program for the analysis of AmB 
Time (minutes) Mobile phase A
a
 (%) Mobile phase B
b
 (%) Flow rate (mL/min) 
0.00 60 40 0.1 
0.01 60 40 0.1 
4.00 0 100 0.1 
5.50 0 100 0.1 
6.00 60 40 0.1 
a
 0.1 M Ammonium acetate pH4; 
b 
Acetonitrile 
Linear calibration curves relating AmB concentration and peak area were made using 
AmB standard solutions in the range of 2 – 0.1 ppm. The quantity of encapsulated AmB in 
uncoated and mannose-coated PLGA nanoparticles was determined by interpolation of 
the peak area, obtained for each sample, in the calibration curve. 
3.3.7.2. FITC 
E.E. of FITC in uncoated and M-, MN- and Ms - coated PLGA nanoparticles was 
determined indirectly by quantification of the non-encapsulated compound that stays in 
the aqueous phase after particle recovery (Aggregates, S1, L1 and L2). FITC have 
intrinsic fluorescence properties exhibiting an excitation and emission wavelength of     
485 nm and 528 nm, respectively, which allows its quantification by measurement of 
fluorescence intensity in a microplate reader. Linear calibration curves relating FITC 
concentration and fluorescence were made in the range of 0.400– 0.003 mg/mL. 
Encapsulation efficiency was determined as: 
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3.3.8. In vitro drug release 
The release of AmB from M-PLGA nanoparticles was determined over time at two pH 
conditions, 5.5, to simulate the release in the endosomal compartment of macrophages, 
and 7.4, to simulate the physiological conditions, and using two different buffers PBS and 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (20 mM). The nanoparticle 
suspension was diluted in the appropriate buffer to a final concentration of 1 mg/mL in 
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polymer and incubated at 37⁰C in a horizontal lab shaker (Thermomixer compact – 
Eppendorf (Hamburg, Germany)) at 500 rpm. At determined intervals samples were 
centrifuged at 20,000 xg for 15 minutes at 4⁰C, the supernatants were collected and 
stored at 4⁰C for quantification of the released compound by UPLC, in the conditions 
previously described. The resulting nanoparticle sediment was re-suspended in fresh 
buffer and re-incubated in the same conditions until next sampling time. 
The release of FITC from uncoated and M-, MN- and Ms -coated PLGA nanoparticles was 
determined over time at pH 7.4, using PBS. The nanoparticle suspension was diluted in 
the appropriate buffer to a final concentration of 1 mg/mL in polymer and incubated at 
37⁰ C in a horizontal lab shaker at 500 rpm. At known intervals samples were centrifuged 
at 20,000 xg for 15 minutes at 4⁰C, the supernatants were collected and stored at 4⁰C for 
quantification of the released compound by measurement of fluorescence intensity in a 
microplate reader. The resulting nanoparticle sediment was re-suspended in fresh buffer 
and re-incubated in the same conditions. 
3.4. Parasites and cell culture 
3.4.1. Parasites 
A cloned line of Leishmania infantum (MOM/MA671TMAP263) promastigotes, stably 
expressing the luciferase gene (LUC), were maintained in culture in RPMI 1640 medium 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine,   
20 mM HEPES, 100 U/mL penicillin and 100 µg/mL streptomycin (all from BioWhittaker, 
Verviers, Belgium) at 26⁰C by sub-passage (106 parasites/mL) every 5 days. Selection of 
LUC-positive parasites was done by adding geneticin sulphate (Sigma-Aldrich, St Louis, 
MO) to the culture media at a final concentration of 5 µg/mL. 
Leishmania infantum axenic amastigotes stably expressing the LUC- gene were derived 
from promastigotes, in stationary phase, by culturing them in MAA (Medium for Axenic 
Amastigotes), that is composed by modified medium  99 with Hank’s balanced salt 
solution (Gibco Invitrogen, Barcelona, Spain) supplemented with 0.5% trypto-casein-soy 
broth (Bio-Rad, Bath, UK), 15 mM D-glucose anhydrous (Panreac, Barcelona, Spain) and 
4 mM NaHCO3 (Sigma Aldrich, St Louis, MO). The pH was adjusted to 5.8 and the media 
was 0.2 µM sterilized by filtration and further supplemented with 0.023 mM bovine hemin 
(Fluka, St Louis, MO), 5 mM L-glutamine and 25% heat-inactivated FBS. Axenic 
amastigotes were maintained in culture at 37⁰C in an atmosphere containing 5% CO2 by 
sub-passage (105 parasites/mL) every 5 days. 
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3.4.2. Human leukaemia monocytic cell line (THP-1 cells) 
The human leukaemia monocytic cell line THP-1 was grown in RPMI 1640 medium 
supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U/mL penicillin and 
100 µg/mL streptomycin. Cells were maintained in culture at 37⁰C in a humidified 
atmosphere containing 5% CO2 by sub-passage every 4 days. The cells were counted in 
a haemocytometer (Marienfeld, Germany) in the presence of trypan blue to exclude non 
viable cells. Human THP-1 cells (105 cells/mL) were differentiated in the presence of      
20 ng/mL phorbol 12-myristate 13-acetate (PMA) (Sigma Aldrich, Sintra, Portugal) for 18h 
at 37⁰ C and were left for another 24h with fresh medium containing no PMA. 
3.4.3. Murine bone marrow-derived macrophages (BMM) – Isolation and 
culture 
Macrophage primary cultures were generated from murine bone marrow precursors from 
femurs and tibias of Balb/c mice in Dulbecco’s modified Eagle’s medium (DMEM) 
(BioWhittaker, Verviers, Belgium), supplemented with 10% heat-inactivated FBS, 2mM   
L-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin in the presence of L929 cell 
conditioned medium (LCCM), as described by [137]. Briefly, femurs and tibias were 
removed from Balb/c mice with 8-10 weeks and in order to promote their disinfection, the 
intact bones were put in 70% ethanol and then washed with PBS. Then both ends of the 
femur were cut with sterile scalpel, and the bone marrow was flushed with cold DMEM 
using a 25G syringe. The obtained cell suspension was cultured in DMEM and after 5 h of 
incubation at 37⁰C non-adherent cells were recovered by centrifugation at 300 xg during 
10 minutes at room temperature and cultured in 24-well plate at 4x105 cells/mL in 5% 
LCCM-supplemented DMEM. For BMM differentiation 5% LCCM was added at days 0 
and 4. If we want to extend further cultured, at day 7 we renew half of the culture medium 
with 5% LCCM-supplemented DMEM. 
3.4.4 Murine bone marrow-derived dendritic cells (BMDCs) – Isolation and 
culture 
Primary cultures of DCs were generated from murine bone marrow precursors from 
femurs and tibias of Balb/c mice in RPMI 1640 medium supplemented with                  
10% heat-inactivated FBS, 2 mM L-glutamine, 100 U/mL penicillin, 100 µg/mL 
streptomycin and β-mercaptoetanol (Sigma Aldrich, Sintra, Portugal), in the presence of 
granulocyte macrophage colony-stimulating factor (GM-CSF) obtained from the 
supernatant of transfected J558 cells. The isolation of bone-marrow cells from femurs and 
tibias were made as described on 3.4.3. section. The obtained cell suspension was 
cultured at a cell density of 5x106 cells in a final volume of 25 mL of complete medium 
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containing 10% GM-CSF. At day 3, more 25 mL of complete medium with 10% GM-CSF 
was added to the culture flasks and at days 6 and 8, half of the culture supernatant was 
collected, centrifuged at 300 xg during 10 minutes, and the cell pellet was re-suspended in 
25 mL of fresh medium containing 5% GM-CSF and put back into the original flask. 
3.5. Toxicity of free AmB and nanoformulations to macrophages 
Differentiated THP-1 macrophages and BMM were incubated in 96-well plates at a cell 
density of 105 cells/mL. Serial dilutions of free AmB and empty or AmB-loaded PLGA 
nanoparticles in culture medium were added to the wells, in quadruplicate, and were 
incubated for 72h at 37⁰C in 5% CO2. Cell viability was assessed by the                       
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay as previously 
described [138]. Briefly, after the incubation period, culture media was removed and cells 
were incubated with the MTT reagent (thyazolyl blue tetrazolium bromide) (Sigma Aldrich, 
St Louis, MO) in culture medium (at 0.5 mg/mL) for 4 hours. After that, we remove the 
medium and add 200 µL of isopropanol to dissolve the formed formazan crystals. Optical 
density (OD) was read at 570 and 660 nm in a microplate reader (Sinergy 2, BioTek). Cell 
viability for each sample was calculated as: 
                  
( D 70 660) treated cells
( D 70 660)untreated cells
  00 
The AmB concentration, either free or in PLGA nanoparticles, necessary to decrease cell 
viability to 50% (EC50) of the untreated control, was determined by linear regression 
analysis. 
3.6. Growth inhibition assays against intracellular Leishmania infantum 
amastigotes 
Differentiated THP-1 macrophages and BMM were incubated in 96-well plates at a cell 
density of 105 cells/mL and subsequently were infected with the stationary phase LUC-
expressing L.infantum axenic amastigotes at a parasite: cell ratio of 10:1, for a period of 
4h, after which the cells were washed with culture medium to remove non-internalized 
parasites. Serial dilutions of free AmB and empty or AmB-loaded PLGA nanoparticles in 
culture medium were added to the wells, in quadruplicate, and were incubated for 72h at 
37⁰C in 5% CO2. After the incubation period, the luciferase activity of intracellular 
amastigotes was determined as previously described [139]. Briefly, culture media was 
removed and cells were incubated during 10 minutes under constant agitation with 100 µL 
of PBS pH7.4 and 25 µL of Glo Lysis Buffer (Promega, Madison, USA) in order to promote 
the cell lysis. After that the luciferase substrate (Steady-Glo® Luciferase) (Promega, 
Madison, USA) was added to the samples (50 µL/well) and incubated under constant 
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agitation and in the dark during 15 minutes. Luminescence was measured in a 
luminometer (Sinergy 2, BioTek) and the values were expressed as relative light units 
(RLU). The percentage of growth inhibition was calculated as: 
 
                    (  
 L  treated cells 
 L  untreated cells
  00) 
 
The AmB concentration, either free or in PLGA nanoparticles, necessary to decrease 
parasite viability to 50% (EC50), was determined by linear regression analysis. 
3.7. Ex vivo and in vivo uptake studies 
3.7.1. Mice 
Six to eight week old male Balb/c mice were obtained from Instituto de Biologia Molecular 
e Celular (IBMC, Porto, Portugal) animal facilities. The animals were maintained in sterile 
cabinets and water and food pellets were provided ad libitum. Animal care and procedures 
were in accordance with institutional guidelines. All conducted experiments were done in 
accordance with the IBMC.INEB Animal Ethics Committee and the Portuguese Veterinary 
Director General guidelines. Sofia Costa Lima has an accreditation for animal research 
given from Portuguese Veterinary Direction (Ministerial Directive 1005/92) and conducted 
the experiments. 
3.7.2. Ex vivo uptake studies 
Splenocytes isolated from the control group (group I), use in the in vivo studies, were 
incubated in 24-well plates at a cell density of 2x106 cells/mL and incubated with        
FITC-loaded PLGA (0.5 mg/mL in polymer) and M-PLGA nanoparticles (1 mg/mL in 
polymer) during 24h. After incubation with nanoparticles, the supernatants were 
recovered, washed by centrifugation (300 xg, 10 min at room temperature) with 
fluorescence activated cell sorting (FACS) buffer (PBS pH 7.4, 2% FBS, 1% P/S and 
0.01% sodium azide) and stained, with CD8-PB, CD4-PerCP, CD3-PeCy7, CD19-APC, 
Ly6C-PerCPCy5.5, Ly6G-PB, CD11b-PeCy7, CD11c-PE and CD206-APC (BioLegend, 
San Diego, CA), at room temperature, during 30 minutes in the dark. The cells were then 
washed and suspended in 200µL of FACS buffer. Data were collected by a BD FACS 
CANTO II flow cytometer and analysed by FlowJo software. 
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3.7.3. Experimental groups 
For the in vivo uptake studies animals were divided into 3 groups, each comprised of      
2-3 mices, and submitted to different treatments, as follows: 
Group I : Control group – mice treated with PBS; 
Group II : Intravenously (i.v.) administration of 0.5 mg/mL in polymer of FITC-
loaded PLGA nanoparticles; 
Group III: Intravenously (i.v.) administration of 1 mg/mL in polymer of FITC-loaded 
M-PLGA nanoparticles. 
3.7.4. In vivo uptake studies 
Two hours after the administration of the nanoparticle formulations (groups II-III) and PBS 
(groups I), mice were euthanized and spleens were isolated, washed in PBS and 
weighted. After that, spleen was homogenized, centrifuged at 300 xg during 10 minutes 
and the final pellet was resuspended in RPMI 1640 medium supplemented with 10% FBS, 
2 mM L-glutamine, 20 mM HEPES, 100 U/mL penicillin and 100 µg/mL streptomycin. The 
number of viable cells was determined by the trypan blue dye exclusion method. 
Splenocytes were then incubated in 96-well plates at a cell density of 106 cells/mL, 
washed thoroughly with cold FACS buffer and stained with the same antibodies used for 
ex vivo uptake studies, at room temperature, during 30 minutes in the dark. The cells were 
then washed and suspended in FACS buffer. Data were collected by a BD FACS CANTO 
II flow cytometer (BD Bioscience, San Jose, California, USA) and analysed by FlowJo 
software. 
3.8. Flow cytometry studies 
3.8.1. Mannose Receptor expression in BMM and BMDCs 
The expression of MR on different days of cell differentiation was evaluated by flow 
cytometry. At days 6, 7, 8 and 9, adherent cells, in the case of BMM, and semi-adherent 
and non-adherent cells, in the case of BMDCs, were recovered and washed by 
centrifugation (300 xg, 10 minutes at room temperature) with cold FACS buffer. Thus, 
BMM were stained with F4/80-FITC and CD206-APC (BioLegend, San Diego, CA), and 
BMDCs with CD11c-PE and CD206-APC (BioLegend, San Diego, CA) at room 
temperature, during 30 minutes in the dark. The cells were then washed and suspended 
in 200 µL of FACS buffer. Data were collected by a BD FACS Calibur flow cytometer and 
analysed by FlowJo software. 
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3.8.2. In vitro uptake and activation studies in BMM and BMDCs 
3.8.2.1. Uptake studies in BMM 
At day 8 of culture, BMM were incubated with uncoated and M-, MN and Ms- coated 
PLGA nanoparticles (0.5 mg/mL in polymer) at different times (30 min, 2h, 6h, 20h and 
24h), in order to study the differential uptake of the nanoparticles. After each time of 
incubation with the nanoparticles adherent cells were washed thoroughly with cold FACS 
buffer, to remove non-internalized nanoparticles, recovered, centrifuged at 300 xg during 
10 minutes and the final pellet was re-suspended in 200µL of FACS buffer. Data were 
collected by a Becton-Dickinson FACS calibur flow cytometer and analysed by FlowJo 
software. 
3.8.2.2. Cell surface markers 
To study the surface co-stimulatory molecules of BMM and BMDCs non-stimulated cells 
and lipopolysaccharide (LPS) (10 µg/mL) (Sigma Aldrich, Sintra, Portugal) treated cells 
were used as negative and positive controls, respectively. 
At day 8 of culture, BMM were incubated with uncoated and M-, MN- and Ms-coated 
FITC-loaded PLGA nanoparticles at a concentration of 1mg/mL in polymer, during 20h. 
After incubation with nanoparticles, cells were washed thoroughly with cold FACS buffer 
to remove non-internalized nanoparticles and then recovered for surface co-stimulatory 
markers analysis. Thus, BMM were stained with CD40-PE, CD86-BV, CD80-
PerCP/Cy5.5, MHCII-Alexa 647, CD206-APC and CD11b-PeCy7 (BioLegend, San Diego, 
CA) at room temperature, during 30 minutes in the dark. The cells were then washed and 
suspended in 200 µL of FACS buffer. Data were collected by a BD FACS CANTO II flow 
cytometer and analysed by FlowJo software. Dead cells were excluded by staining with  
7-AAD and the intensity of the expression of each cell surface marker was reported as 
mean fluorescence intensity (MFI) of CD11b+/7-AAD- cells. 
At day 8 of culture, BMDCs were incubated in a 24-well plate at a cell density of            
106 cells/mL and left over-night at 37⁰C in an atmosphere containing 5% CO2. At day 9, 
cells were incubated with uncoated and M-, MN- and Ms-coated FITC-loaded PLGA 
nanoparticles at a concentration of 1mg/mL in polymer, during 20h. After incubation with 
nanoparticles, semi-adherent and non-adherent cells were recovered, washed thoroughly 
by centrifugation (300 xg, 10 minutes at room temperature) with cold FACS buffer to 
remove non-internalized nanoparticles, and then recovered for surface co-stimulatory 
markers analysis. Thus, BMDCs were stained with CD40-PeCy7, CD86-BV, MHCII-Alexa 
647, CD206-APC, CD11c-PE and 7-AAD-PerCPCy5 (BioLegend, San Diego, CA) at room 
temperature, during 30 minutes in the dark. The cells were then washed and suspended 
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in 200 µL of FACS buffer. Data were collected by a BD FACS CANTO II flow cytometer 
and analysed by FlowJo software. Dead cells were excluded by staining with 7-AAD and 
the intensity of the expression of each cell surface marker was reported as MFI of 
CD11c+/7-AAD- cells. 
3.8.2.3. Intracellular cytokines 
In order to study the production of intracellular cytokines by BMM and BMDCs              
co-cultured with mannosylated PLGA nanoparticles we perform the procedure described 
in section 3.8.2.2., being that, in this case, after 20h of co-culture with nanoparticles and 
the cells were incubated with 50 ng/mL of PMA and 500 ng/mL Ionomycin (Sigma Aldrich, 
Sintra, Portugal) during 2h at 37⁰C, 5% CO2. The cells were then incubated for more 2h, 
at 37⁰C, 5% CO2, with 10 µg/mL of brefeldin A. After that, the cells were recovered and in 
the case of BMM the surface staining was performed during 30 minutes in the dark using 
the CD11b-PeCy7 antibody. The fixation of the cells were achieved by incubation during 
20 minutes at room temperature with paraphormaldehyde 2% (PFA) (Merck , Darmstadt, 
Germany) and after that time the cells were washed and permeabilized using a 
permeabilization buffer (10% saponin and FACS buffer). Thus cells were stained with     
IL-12 - APC, IL-6 - APC, IL-4 - PE and TN α – PerCPCy5.5 (BioLegend, San Diego, CA) 
at room temperature, during 30 minutes in the dark. The cells were then washed and 
suspended in 200µL of FACS buffer. Data were collected by a BD FACS CANTO II flow 
cytometer and analyzed by FlowJo software. 
3.9. Fluorescence microscopy analysis of nanoparticle uptake by BMM 
At day 8 of culture, BMM, previously platted in coverslips at a cell density of 4x105, were 
incubated with uncoated and M-, MN- and Ms-coated FITC-loaded PLGA nanoparticles at 
a concentration of 1mg/mL in polymer, during 20h. After that time cells were washed three 
times with PBS pH 7.4, to remove extracellular and non-adherent nanoparticles, and fixed 
for 20 minutes with 2% PFA in PBS. Then the fixed cells were washed and the coverslips 
were mounted on glass slides using mounting medium with DAPI, VectaShield (Vector 
Laboratories). Cells were examined in the fluorescence microscope AxioImager Z1 (Carl 
Zeiss, Germany). 
3.10. Statistical Analysis 
Statistical analysis was performed by one-way ANOVA followed by Tukey test or 
Dunnett’s multiple comparison test. 
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IV. RESULTS 
4.1. Mannosylated nanoparticles for VL therapy 
Since current therapies against VL have several drawbacks it is of great importance to 
develop alternative treatments, like nanotechnology-based drug delivery systems, that 
replace or complement the ones that are already available. Thus, one of the aims of this 
work was to prepare a targeting delivery system to overcome some of the weaknesses 
and allowing a more efficient delivery of drugs, namely of AmB. 
The MR is a member of CLR family, highly expressed on APCs, that was selected to 
functionalize nanoparticles for targeting and delivery of drugs towards              
Leishmania-infected macrophages. Three different techniques, PA, CR1 and CR2, were 
conducted to prepare unloaded M-PLGA nanoparticles. After the physicochemical 
characterization of the produced nanoparticles, AmB was encapsulated on the M-PLGA 
nanoparticles and their efficiency as drug delivery system evaluated in vitro in 
Leishmania-infected macrophages. Ex vivo and in vivo studies, using splenocytes isolated 
from Balb/c mice, were also performed, in order to verify if M-PLGA nanoparticles 
effectively target APCs. 
4.1.1. Preparation and characterization of unloaded M-PLGA nanoparticles 
Unloaded M-PLGA nanoparticles were prepared by three different techniques, PA, CR1 
and CR2, and were evaluated based on the physicochemical characterization of the 
produced nanoparticles, in order to see which of those techniques is/are more suitable for 
their preparation. 
Physicochemical characterization of the nanoformulations included size, PDI, zeta 
potential, mannose coating efficiency, morphology, confirmation of the molecular structure 
of nanoparticles and assessment of mannose surface orientation. 
4.1.1.1. Size, PDI, zeta potential and mannose quantification 
Table 3 summarizes the physicochemical characteristics of the prepared 
nanoformulations before and after mannose functionalization. 
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Table 3 - Physicochemical characteristics of M- PLGA nanoparticles 
a 
Nanoparticles 
Coating 
Reaction 
Size (nm) PDI 
ζ- Potential 
(mV) 
Mannose 
(mg/mg 
polymer)
b
 
PLGA - 205.5 ± 7.3 0.072 ± 0.001 -12.50 ± 0.90 - 
M-PLGA 
PA 221.9 ± 2.6 0.060 ± 0.002 -16.80 ± 0.01* 1.87 ± 0.01 
CR1 195.0 ± 8.2 0.036 ± 0.001 -27.00 ± 2.50*** 1.90 ± 0.01 
CR2 199.8 ± 1.8 0.061 ± 0.011 -22.20 ± 0.07** 1.87 ± 0.01 
PA, physical adsorption; CR1, one-step chemical reaction; CR2, two-step chemical reaction 
a 
Values are presented as mean ± standard deviation of three independent experiments 
b 
Indirect quantification by phenol-sulfuric acid reaction 
*P<0.05; **P<0.0 ; ***P<0.00  compared with ζ-potential of uncoated PLGA nanoparticles 
The uncoated PLGA nanoparticles prepared by the nanoprecipitation method [5] 
presented a mean diameter of 205.5 ± 7.3 nm and a low PDI (<0.1) that suggests an 
homogeneous distribution of nanoparticle size. 
Mannosylated nanoformulations prepared by the three different techniques (PA, CR1 and 
CR2) exhibited a mean diameter in the range of 195 – 222 nm and a low PDI (<0.1). No 
statistically significant differences in size were observed between the M-coated and the 
uncoated nnoparticles. 
Uncoated PLGA nanoparticles have an anionic surface charge of -12.5 ± 0.9 mV. The 
coating of these nanoparticles with mannose leads to a statistically highly significant 
increase (P<0.001), in absolute value, of zeta potential for values in the -16 to -27 mV 
range. The M-PLGA nanoparticles produced by PA (-16.80 ± 0.01 mV) has a statistically 
significant surface charge when compared with uncoated nanoparticles (P<0.05), while 
the chemical reaction methods (CR1 and CR2) lead to statistically highly significant 
anionic charges (-27.00 ± 2.50, P<0.001 and -22.20 ± 0.07 mV, P<0.01; respectively) on 
the M-PLGA nanoparticles surface. Anionic surface charge in M-PLGA nanoparticles 
followed this trend: CR1 > CR2 > PA. 
The effect of the coating method on the incorporation level of mannose was investigated 
by indirect quantification using phenol-sulfuric acid reaction. The quantity of mannose 
present in larger particle aggregates and supernatants obtained from the washing steps 
was very low, leading to a yield around 94% for each of the three techniques. 
4.1.1.2. Transmission electron microscopy 
The morphology of M-PLGA nanoparticles prepared by the each different technique was 
observed using TEM. The photographs suggested that M-PLGA nanoparticles prepared 
by PA and CR1 (Fig.12B-C) exhibit spherical shape, whereas the ones that are prepared 
by CR2 (Fig.12D) were relatively less spherical and smooth. The nanoparticles prepared 
A B C D 
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by PA tend to form aggregates, which can be explained by the fact of this nanoparticles 
have a lower, in absolute value, zeta potential value (-16.80 ± 0.01 mV). 
Figure 12 - TEM photomicrographs of uncoated PLGA (A) and PLGA coated with mannose by physical 
adsorption (B), one-step chemical reaction (C) and two-step chemical reaction (D) at 50,000 magnifications. 
Bars represent 500 nm. 
 
4.1.1.3. Fourier transformed infrared spectroscopy 
 
 
 
 
 
 
Figure 13 - FTIR spectrum of uncoated (A) and mannose-coated by chemical reaction (B) PLGA 
nanoparticles. 
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FTIR is a technique used for chemical characterization of nanoparticles, being particularly 
important in cases where there is a surface modification. Through this technique it is 
possible to detect strong chemical bonds (e.g. covalent bond). Thus, in this work a FTIR 
analysis was performed to confirm the presence of mannose linked to the polymer, by 
CR1 and CR2, and verify if the covalent binding between this ligand and PLGA occurred. 
According to the literature, the peak correspondent to the covalent binding between 
mannose and PLGA is around 1630 cm-1 [29]. 
The FTIR spectrum obtained for M-PLGA nanoparticles prepared by CR1 and CR2 were 
similar, and in Fig.13B is possible to see a more prominent peak at 1625 cm-1, 
representing the covalent binding of mannose and PLGA, that is not observed in the FTIR 
spectrum of uncoated PLGA nanoparticles Fig. 13A. 
4.1.1.4. Lectin binding assay 
To assess the surface orientation and the availability of mannose ligand after formation of 
coated PLGA nanoparticles, an agglutination assay using ConA lectin was conducted. 
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Figure 14 - In vitro ligand agglutination of M-PLGA nanoparticles using 25 µg/mL of ConA (PA – physical 
adsorption; CR – chemical reaction). Values represent mean ± standard deviation of two independent 
experiments. Comparison of absorbance values, measured at 550 nm, of M-PLGA nanoparticles prepared by 
PA and CR (** P<0.01). 
Following exposure to 25 µg/mL of ConA an increase in the absorbance at 550 nm was 
observed for M-PLGA nanoparticles prepared by either PA or CR (Fig.14). The extent of 
agglutination, for nanoformulations prepared by any of the three techniques, rapidly 
increases up to 10 minutes and from here after remains almost constant, which may be 
due to saturation of the binding sites. 
It is clear by statistically significant higher absorbance (P<0.01) that mannose in 
nanoparticles prepared by either CR1 or CR2 interact in a greater extent with ConA when 
compared with mannose in nanoparticles prepared by PA. 
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4.1.2. In vitro evaluation of M- PLGA nanoparticles 
4.1.2.1. Toxicity of M- PLGA nanoparticles to macrophages 
The toxicity of unloaded M-PLGA nanoparticles, prepared by PA, CR1 and CR2, was 
evaluated in Leishmania-host cells (THP-1 differentiated macrophages), used later in the 
infection assays, by the MTT assay. As illustrated in Fig.15 the THP-1 cells exhibited 
more than 80% viability after 3 days in the presence of 0.25 – 2.0 mg/ml of any of the 
three nanoformulations, which means that these do not exhibit significant toxicity towards 
mammalian cells.  
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Figure 15 - Viability of human THP-1 differentiated macrophages following treatment with increasing 
concentrations of unloaded M-PLGA nanoparticles prepared by three different techniques. Values represent 
mean ± standard deviation of three independent experiments. 
4.1.2.2. Antileishmanial activity of M-PLGA nanoparticles against L. infantum 
intracellular amastigotes 
The ability of unloaded M-PLGA nanoparticles, prepared by PA, CR1 and CR2, to inhibit 
the growth of L. infantum intracellular amastigotes was evaluated through the 
determination of the parasites luciferase activity. 
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Figure 16 - Biological activity of unloaded M-PLGA nanoparticles prepared by each of the three different 
techniques against intracellular L. infantum amastigotes. Values represent mean ± standard deviation of three 
independent experiments. 
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As illustrated in Fig.16 M-PLGA nanoparticles prepared by any of the three techniques are 
not able, per se, to inhibit the growth of L. infantum intracellular amastigotes at 
concentration below 2 mg/ml in polymer within a 72h period of incubation. 
4.1.3. Storage stability of unloaded M-PLGA nanoparticles prepared by one-
step chemical reaction  
CR1 was the reaction chosen to prepare M-PLGA nanoparticles, since the nanoparticles 
prepared using this reaction, in comparison with the others, exhibit a small mean diameter 
(195.0 ± 8.2 nm), a low PDI (0.036 ± 0.001), good stability (-27.00 ± 2.50 mV), were 
spherical in shape and interact in a greater extent with ConA. So, the next step was 
conducted to evaluate the storage stability of these nanoparticles at different temperature 
conditions: -20⁰C, 4⁰C and 37⁰C. From the same batch of nanoparticles, aliquots were 
stored at different temperatures and periodically analyzed for size, PDI and zeta potential 
by DLS. 
 
 
 
Figure 17 – Storage stability at -20⁰C, 4⁰C and 37⁰C of unloaded M-PLGA nanoparticles prepared by one-
step chemical reaction. (A) Size; (B) PDI; and (C) Zeta Potential. Values are presented as mean ± standard 
deviation of two measurements. *P<0.05; **P<0.01; ***P<0.001 compared with values at day 0 of each 
measured parameter. 
As illustrated in Fig.17A no significant changes in size, with a mean of 212.4 ± 5.6 nm, 
was observed when M-PLGA nanoparticles were stored for a period of 8 weeks at 4⁰C. 
However, a statistically highly significant (P<0.001) increase on average size was 
observed for M-PLGA nanoparticles stored at -20⁰C, thus verifying that at the end of 1 day 
of storage, at this temperature, the nanoparticles already present a ≈2-fold increase in 
their size (406.5 nm compared with the 213.2 nm at day 0). This trend is maintained over 
the 8 weeks of storage. Although in the case of M-PLGA nanoparticles stored at 37⁰C we 
also see a statistically highly significant (P<0.001) increase in size, this only occurs at the 
end of 2 weeks of storage (280.2 nm compared with the 213.2 nm at day 0). 
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In what concerns PDI values (Fig. 17B), once again, no significant changes was observed 
for nanoparticles stored at 4⁰C, with the values remaining more a less the same over the  
8 weeks of storage (0.062 at day 0 and 0.067 after 8 weeks of storage). On the other 
hand, a statistically highly significant (P<0.001) increase was observed for M-PLGA 
nanoparticles stored at -20⁰C (PDI > 0.40) and 37⁰C (PDI > 0.15), being that increase 
more prominent in the ones stored at negative temperatures. 
Zeta potential of M-PLGA nanoparticles (Fig.17C) stored at 4⁰  doesn’t significantly 
change with the time of storage (-24.4 mV at day 0 and -22.0 mV after 8 weeks of 
storage). At -20⁰C and 37⁰C the zeta potential becomes less negative with time, being this 
decrese more prominent for the nanoparticles that are stored at 37⁰C (-24.4 mV at day 0 
and -6.7 mV after 8 weeks of storage). 
4.1.4. Characterization of AmB-loaded M-PLGA nanoparticles 
The application of the mannose-coated nanoparticulate system developed previously in 
section 4.1.1., for efficient delivery of AmB, was evaluated in vitro using           
Leishmania-infected macrophages. AmB was successfully incorporated into uncoated 
PLGA nanoparticles by the nanoprecipitation method [5] and mannose was both 
physically and chemically conjugated to PLGA nanoparticles. 
Physicochemical characterization of the nanoformulations included size, PDI, zeta 
potential, mannose coating efficiency, E.E., morphology and in vitro drug release. 
4.1.4.1. Size, PDI, zeta potential, mannose quantification and E.E. 
Table 4 summarizes the physicochemical characteristics of the prepared AmB-loaded 
nanoformulations before and after mannose coating. 
Table 4 - Physicochemical characteristics of uncoated and coated PLGA nanoparticles loaded with AmB 
a 
Nanoparticles 
Coating 
Reaction 
Size (nm) PDI 
ζ- Potential 
(mV) 
Mannose 
(mg/mg 
polymer)
b 
E.E. (%)
c
 
PLGA AmB - 208.0 ± 0.3 0.083 ± 0.003 -12.58 ± 0.23 - 20.0 ± 1.1 
M-PLGA AmB 
PA 200.2 ± 10.7 0.085 ± 0.004 -14.66 ± 0.25** 1.90 ± 0.02 1.8 ± 0.0*** 
CR1 190.8 ± 6.4* 0.076 ± 0.002 -16.21 ± 0.90*** 1.96 ± 0.02 4.1 ± 0.0*** 
PA, physical adsorption; CR1, one-step chemical reaction 
a 
Values are presented as mean ± standard deviation of three independent experiments 
b 
Indirect quantification by phenol-sulfuric acid reaction 
c
 Direct quantification by UPLC 
*P<0.05, **P<0.01, ***P<0.001 compared with AmB-loaded PLGA nanoparticles 
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The incorporation of AmB in PLGA nanoparticles leads to a statistically significant 
increase (P<0.01) in their size (208.0 ± 0.3 nm) (Table 4), when compared to empty PLGA 
nanoparticles (205.5 ± 7.3 nm) (Table 3). The AmB-loaded PLGA nanoparticles presented 
a low PDI (<0.1) that suggests a homogeneous distribution of the nanoparticle size. The 
mannose-coating of this nanoparticles by PA does not lead to a significant change in the 
mean diameter (200.2 ± 10.7 nm), however when the CR1 is used a statistically significant 
decrease (P<0.05) (190.8 ± 6.4 nm) was observed. Both mannosylated nanoformulations 
present a low PDI (<0.1). 
AmB-loaded PLGA nanoparticles have an anionic surface charge of -12.6 mV. The 
coating of these nanoparticles with mannose, either by PA or CR1, leads to a statistically 
significant increase, in absolute value, of zeta potential for values of -14.7 mV (P<0.01) 
and -16.2 mV (P<0.001), respectively. 
The coating level of mannose was investigated by indirect quantification using phenol-
sulfuric acid reaction. The quantity of mannose present in larger particle aggregates and 
supernatants obtained from the washing steps was very low, leading to a yield around 
95% for nanoparticles prepared by PA and around 98% for the ones prepared by CR1. 
E.E. of AmB in uncoated and mannose-coated PLGA nanoparticles was determined 
directly by UPLC, as described in section 3.3.7.1. Uncoated PLGA nanoparticles have an 
E.E. of 20%, being that the coating of these nanoparticles with mannose, either by PA or 
CR1, leads to a statistically highly significant decrease (P<0.001) on the E.E., for values of 
1.8% and 4.1%, respectively. 
4.1.4.2. Transmission electron microscopy 
The morphology of AmB-loaded PLGA nanoparticles, either uncoated or mannose-coated 
by PA and CR1, was observed by TEM (Fig.18). 
 
 
 
 
 
Figure 18 - TEM photomicrographs of AmB-loaded uncoated (A) and mannose-coated by PA (B) and CR1 
(C) PLGA nanoparticles at 50,000 magnifications. Bars represent 500 nm. 
TEM photographs showed that although all nanoformulations were spherical in shape the 
AmB-loaded M-PLGA nanoparticles prepared by CR1 have a more heterogeneous 
surface, with some of them presenting a rough surface and others a smooth surface. 
A B C 
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4.1.4.3. In vitro release of AmB 
Release of AmB from M-PLGA nanoparticles, prepared either by PA or CR1, was 
determined over time at two pH conditions, 5.5, to simulate the release in the endosomal 
compartment of macrophages, and 7.4, to simulate the physiological conditions, and using 
two different buffers PBS and HEPES. 
 
 
 
Figure 19 - In vitro release profile of AmB from M-PLGA nanoparticles prepared by PA (A) and CR1 (B) under 
physiological (HEPES and PBS pH 7.4) and acidic (PBS pH 5.5) conditions. Values are presented as mean ± 
standard deviation of two measurements. *P<0.05; **P<0.01 comparison of the % cumulative release of AmB 
from M-PLGA nanoparticles in different incubation conditions. 
 
Table 5 - Comparison of the percentage of cumulative release of AmB from M-PLGA nanoparticles, prepared 
either by PA or CR1, after 2 weeks, incubated under the same conditions 
Nanoformulation 
Coating 
reaction 
% Cumulative release 
HEPES 7.4 PBS 7.4 PBS 5.5 
M-PLGA AmB 
PA 53.20 ± 0.02 44.25 ± 1.07 36.58 ± 1.45 
CR1 43.07 ± 0.41*** 32.21 ± 0.96** 31.19 ± 0.09* 
Values are presented as mean ± standard deviation of two measurements. *P<0.05; **P<0.01; ***P<0.001 comparison 
between % cumulative release of AmB from nanoparticles prepared by PA and CR1. 
The AmB-loaded M-PLGA nanoparticles, prepared by PA or CR1, exhibited a triphasic 
release profile, that include an initial moderate release of 15 to 20% in the first 24 hours, a 
fast release, of 30 to 40% in the following 6 days, and a last phase in which we observe a 
sustained release of the drug lasting for 1 week (Fig.19). 
The maximum release percentage of AmB in M-PLGA nanoparticles, prepared either by 
PA or CR1, was observed when these nanoformulations were incubated in HEPES pH 
7.4, while significantly lower release was observed when incubated under acidic 
conditions, PBS pH 5.5 (Fig. 19). 
Although the release profile of AmB is similar for M-PLGA nanoparticles prepared by PA 
and CR1, a slower and more controlled release is observed, for all experimental 
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conditions, in the ones prepared by CR1 (Fig.19 and Table 5), which is in accordance with 
the fact of these nanoparticles have a much more stable structure resulting from the 
covalent bond between mannose and PLGA. 
4.1.5. In vitro evaluation of AmB-loaded M- PLGA nanoparticles 
4.1.5.1. Toxicity of AmB-loaded M- PLGA nanoparticles to macrophages 
The toxicity of free AmB, uncoated and mannose-coated AmB-loaded PLGA 
nanoparticles, was evaluated in human THP-1 differentiated macrophages and murine 
BMM by the MTT assay (Table 6). 
Table 6 - Cytotoxicity of free AmB and nanoformulations to human THP-1 differentiated macrophages and 
murine BMM 
Formulation Coating reaction EC50 (µM)
a
 
  THP-1 BMM 
Free AmB  19.8 ± 3.6 21.8 ± 2.8 
PLGA AmB  >100 >100 
M-PLGA AmB 
PA >50 >50 
CR1 >50 >50 
EC50 (half maximal effective concentration), concentration of a compound necessary to decreased cell viability to 50% of the 
untreated control; PA, physical adsorption; CR1, one-step chemical reaction. 
a 
Values are presented as mean ± standard deviation of three independent experiments 
The incorporation of AmB into uncoated and mannose-coated PLGA nanoparticles 
decreased by ≈  - and 2.5-fold, respectively, its toxicity to human THP-1 differentiated 
macrophages and BMM, in comparison with free AmB. 
4.1.5.2. Growth inhibition of AmB-loaded M-PLGA nanoparticles against 
Leishmania infantum intracellular amastigotes 
The antileishmanial activity of free AmB, uncoated and mannose-coated AmB-loaded 
PLGA nanoparticles was evaluated on human THP-1 differentiated macrophages and 
murine BMM infected with L.infantum intracellular amastigotes (Table 7). 
The incorporation of AmB into uncoated PLGA nanoparticles, leads to an increased 
statistically highly significant (P<0.001) of the efficacy of the compound in inhibiting 
intracellular amastigote growth, in comparison to free AmB. On the other hand, the values 
of EC50 obtained for AmB incorporated in mannose-coated PLGA nanoparticles, either by 
PA or CR1, show a statistically highly significant (P<0.001) improvement, both in THP-1 
cells and BMM, of the drug antileishmanial activity in the nanoformulations, perhaps 
related with a more efficient uptake.  
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Table 7 - Antileishmanial activity of free AmB and nanoformulations against Leishmania infantum intracellular 
amastigotes in human THP-1 differentiated macrophages and murine BMM 
Formulation Coating reaction EC50 (nM)
a
 
  THP-1 BMM 
Free AmB  1320.2 ± 151.5 1134.6 ± 91.0 
PLGA AmB  140.8 ± 21.6*** 146.1 ± 7.6*** 
M-PLGA AmB 
PA 13.0 ± 2.2*** 5.2 ±0.6*** 
CR1 4.3 ± 0.3*** 5.0 ± 0.1*** 
EC50 (half maximal effective concentration), concentration of a compound necessary to decreased intracellular parasite 
viability to 50% of the untreated control; PA, physical adsorption; CR1, one-step chemical reaction. 
a 
Values are presented as mean ± standard deviation of three independent experiments 
*** P<0.001 compared with free AmB 
4.1.6. Preparation and characterization of FITC-loaded nanoparticles 
FITC-loaded uncoated and M-coated PLGA nanoparticles were prepared for ex vivo and 
in vivo studies by the nanoprecipitation method [5]. For the studies described later on 
section 4.2 (Mannosylated nanoparticles for immunotherapy) two other sugars (MN and 
Ms) were chemically conjugated to PLGA nanoparticles, using CR1 method, after 
encapsulation of FITC, being that their description will be included herein. 
Physicochemical characterization of the nanoformulations included size, PDI, zeta 
potential, sugar coating efficiency, E.E. and in vitro drug release. 
4.1.6.1. Size, polydispersity index, zeta potential, sugar quantification and 
E.E. 
Table 8 summarizes the physicochemical characteristics of the prepared 
nanoformulations before and after the incorporation of different sugars. 
Table 8 - Physicochemical characteristics of uncoated and coated PLGA nanoparticles loaded with FITC
a 
Nanoparticles Size (nm) PDI 
ζ-Potential 
(mV) 
Sugar 
(mg/mg 
polymer)
b
 
E.E. (%)
c 
PLGA FITC 201.2 ± 7.5 0.057 ± 0.002 -12.17 ± 0.69 - 56.4 ± 4.1 
M-PLGA FITC 188.5 ± 6.7 0.063 ± 0.002 -19.03 ± 1.10*** 1.96 ± 0.01 56.1 ± 4.2 
MN-PLGA FITC 191.5 ± 7.4 0.066 ± 0.004* -18.03 ± 1.44*** 1.82 ± 0.01 56.0 ± 4.2 
Ms-PLGA FITC 184.0 ± 0.9* 0.084 ± 0.004*** -14.55 ± 0.57* 1.99 ± 0.01 56.1 ± 4.1 
a 
Values are presented as mean ± standard deviation of three independent experiments. 
b 
Indirect quantification by phenol-sulfuric acid reaction. 
c
 Indirect quantification by fluorimetry 
*P<0.05, ***P<0.001 compared with FITC-loaded PLGA nanoparticles. 
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FITC-loaded PLGA nanoparticles revealed a mean diameter of 201.2 ± 7.5 nm and a low 
PDI (<0.1) that suggests a homogeneous distribution of nanoparticle size. No statistically 
significant differences on the average diameter were observed between the M- and MN-
PLGA and uncoated PLGA nanoparticles (Table 8). A statistically significant decrease in 
the size of Ms-PLGA (184.0 ± 0.9 nm, (P<0.05) when compared with uncoated PLGA 
nanoparticles was detected. Although mannose coating did not cause a significant change 
in the PDI (0.063 ± 0.002) of nanoparticles, when compared with uncoated PLGA 
nanoparticles (0.057 ± 0.002), the incorporation of MN and Ms lead to a statistically 
significant increase of the PDI values (0.066 ± 0.004 (P<0.05) and 0.084 ± 0.004 
(P<0.001)), respectively. 
FITC-loaded PLGA nanoparticles have an anionic surface charge of -12.2 ± 0.7 mV. The 
coating of these nanoparticles with M, MN and Ms leads to a statistically significant 
increase, in absolute value, of zeta potential for values of -19.0 ± 1.1 (P<0.001),                
-18.0 ± 1.4 (P<0.001) and -14.6 ± 0.6 mV (P<0.05), respectively. 
The incorporation level of the different sugars was investigated by indirect quantification 
using the phenol-sulfuric acid reaction. The quantity of mannose present in larger particle 
aggregates and supernatants obtained from the washing steps was very low, leading to a 
yield around 98% for M-coated, 91% for MN-coated and 99% for Ms-coated PLGA 
nanoparticles. 
E.E. of FITC was determined indirectly by quantification of the non-encapsulated 
compound as described in section 3.3.7.2.. An E.E. of FITC around 56% were achieved in 
all prepared nanoformulations, being that no significant differences were observed 
between uncoated and coated nanoparticles (Table 8). 
4.1.6.2. In vitro release of FITC 
Release of FITC from uncoated, M-, MN- and Ms-coated PLGA nanoparticles was 
determined over time at physiological conditions using PBS pH 7.4. 
 
 
 
 
 
 
 
Figure 20 - In vitro release profile of FITC from uncoated, M-, MN- and Ms- coated PLGA nanoparticles under 
physiological conditions (PBS 7.4). Values are presented as mean ± standard deviation of two measurements. 
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No significant differences were observed in the release profiles of uncoated, M-, MN- and 
Ms-coated PLGA nanoparticles (Fig.20). The FITC-loaded nanoparticles presented a 
biphasic pattern of release with an initial burst of release of about 3.2 % in the first two 
hours that is followed by a constant release of the compound that at the end of the 
incubation period, 3 0h, remains ≈3.2%. 
4.1.7. Ex vivo and in vivo uptake studies 
To demonstrate that M-PLGA nanoparticles are directed to APCs (macrophages and 
DCs), ex vivo and in vivo studies, using splenocytes isolated from Balb/c mice were 
conducted in order to evaluate their differential uptake by lymphocytes (T cells (CD4+ and 
CD8+) and B cells), APCs (macrophages and DCs) and neutrophils. 
4.1.7.1. Ex vivo uptake studies 
Ex vivo uptake studies were performed using the splenocytes isolated from Balb/c mice 
that received intravenously PBS (control group). Splenocytes were co-cultured for 24h 
with FITC-loaded uncoated and mannose-coated PLGA nanoparticles. The differential 
uptake of nanoparticles by T cells, B cells, APCs (macrophages and DCs) and neutrophils 
was assessed by flow cytometry and the results are expressed in percentage and in total 
number of cells calculated relative to the total number of spleen cells. 
Splenocytes were predominantly composed by lymphocytes, with a significant high 
number of B cells (35.5% of total cells), comparatively with CD4+T cells (30.6%) and 
CD8+T cells (10.6%). APCs and neutrophils represent, in turn, a small percentage of total 
cells in spleen (macrophages – 3.4%; DCs – 0.8% and neutrophils – 1.1%). The 
percentages values represent the mean of the percentages obtained for two independent 
experiments performed in duplicate. Fig.21 reveal that in splenocytes co-cultured with 
uncoated and M-coated PLGA nanoparticles, the uptake occurs preferentially by APCs 
and neutrophils (Fig.21B-F), with no significant differences in the number of cells 
containing each type of nanoparticles. 
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Figure 21 – Ex vivo evaluation of the differential uptake of FITC-loaded uncoated and M-coated PLGA 
nanoparticles by T cells (CD4
+
 and CD8
+
), B cells, APCs and neutrophils. (A) percentage of total spleen cells; 
(B) total cell number in the spleen; (C) percentage of spleen cells containing FITC-loaded PLGA 
nanoparticles; (D) total cell number containing FITC-loaded PLGA nanoparticles; (E) percentage of spleen 
cells containing FITC-loaded M-PLGA nanoparticles; (F) total cell number containing FITC-loaded M-PLGA 
nanoparticles. Results are expressed as the mean ± standard deviation of two independent experiments 
performed in duplicate. 
4.1.7.2. In vivo uptake studies 
For the in vivo, studies Balb/c mice were intravenously administered with PBS (control 
group) or FITC-loaded uncoated and mannose-coated PLGA nanoparticles. After 2h, the 
animals were euthanized and the spleen recovered to assess, by flow cytometry, the 
differential uptake of nanoparticles by T cells, B cells, APCs (macrophages and DCs) and 
neutrophils. The results are expressed in percentage and in total number of each type of 
cells calculated relative to total number of spleen cells. 
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Analysis of the cell composition of splenocytes revealed a predominance of lymphocytes, 
with a significant high number of B cells (32.1% of total cells), comparatively with CD4+T 
cells (25.9%) and CD8+T cells (8.7%). APCs and neutrophils represent, in turn, a small 
percentage of total cells in spleen (macrophages – 2.3%; DCs – 0.7% and         
neutrophils – 0.5%). The percentages previously shown represent the mean of the 
percentages obtained for one experiment performed in duplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22 – In vivo evaluation of the differential uptake of FITC-loaded uncoated and mannose-coated PLGA 
nanoparticles by T cells (CD4
+
 and CD8
+
), B cells, APCs and neutrophils. (A) percentage of total spleen cells; 
(B) total cell number in the spleen; (C) percentage of spleen cells containing FITC-loaded PLGA 
nanoparticles; (D) total cell number containing FITC-loaded PLGA nanoparticles; (E) percentage of spleen 
cells containing FITC-loaded M-PLGA nanoparticles; (F) total cell number containing FITC-loaded M-PLGA 
nanoparticles. Results are expressed as the mean ± standard deviation of one experiment performed in 
duplicate. 
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In splenocytes isolated from mice treated with FITC-loaded PLGA nanoparticles it is 
observed that, although lymphocytes constitute the main population of cells in spleen, the 
uptake occurs preferentially by APCs and neutrophils (Fig.22C-D). In the case of mice 
treated with FITC-loaded M-PLGA nanoparticles, contrarily to what would be expected, 
APCs present an uptake similar to what is observed for lymphocytes (Fig.22E-F). On the 
other hand neutrophils present a higher uptake of nanoparticles comparatively with the 
other types of cells however it is significantly lower than that of PLGA formulations 
(Fig.22C-F). 
The results of in vivo studies follow the same trend of the ones obtained on ex vivo 
studies. 
4.2. Mannosylated nanoparticles for immunotherapy 
Active targeting of nanoparticles to MR can potentially modulate macrophages and DCs 
improving their efficacy in the induction of an immune response [6-8]. 
In order to characterize the modulation of mannosylated nanoparticles on APCs, PLGA 
nanoparticles were functionalized with three different sugars, M, MN and Ms. Bone 
marrow derived macrophages and DCs were co-culture with each of these mannosylated 
nanoparticles and the expression of cell surface markers and intracellular cytokines 
production evaluated by flow cytometry. 
4.2.1. Mannose receptor expression in BMM 
The expression of MR on different days of BMM differentiation was evaluated by FACS. 
F4/80 was used as a macrophage marker in order to determine the percentage of BMM 
expressing MR. Results in Fig.23A-D, representative of 3 independent experiments, 
showed that MR expression is time-dependent, being the maximum expression of this 
receptor observed on day 8 of differentiation (77.9% cells F4/80+ / MR+). At day 9 is 
possible to observe a significant reduction in the expression of MR (49.5% cells 
F4/80+/MR+). 
Taking into consideration the previous results, in the following studies BMM with 8 days 
of differentiation were used. 
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Figure 23 - Mannose receptor expression on different days of murine bone-marrow derived macrophages 
differentiation. (A) Histograms representing the MR expression at days 6, 7, 8 and 9. The pink and green 
colors represent F4/80
+
 control cells and F4/80
+
/MR
+
 cells, respectively. (B) Dot plot of BMM at day 8 of 
differentiation showing percentage of cells positive for F4/80 and MR. The results shown are representative of 
three independent experiments. 
4.2.2. In vitro BMM uptake studies 
4.2.2.1. Uptake studies – Flow cytometry 
Uptake studies were performed in BMM with 8 days of differentiation co-cultured with 
each of the mannosylated nanoparticles (M-PLGA, MN-PLGA and Ms-PLGA). 
Results (Fig.24A-D) show that after 30 minutes the non-functionalized and mannosylated 
nanoparticles had already been taken up by BMM. In the subsequent times a slight shift 
of the fluorescence peak was observed, suggesting continuous cell uptake of the 
nanoformulations. 
A B 
B 
A 
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Figure 24 - Uptake of FITC-loaded (A) PLGA, (B) M-PLGA, (C) MN-PLGA and (D) Ms-PLGA nanoparticles by 
BMM at different incubation times (30 min, 2h, 6h, 20h and 24h). The results shown are representative of two 
independent experiments. 
In posterior in vitro studies an incubation time of 20h was used to assure that 
nanoparticles are in contact with cells enough time to modulate cell activation status. The 
differential uptake of non-functionalized and mannosylated nanoparticles is shown on 
Fig.25, revealing a significant higher fluorescence intensity for the uncoated nanoparticles 
(PLGA nanoparticles). 
 
 
 
 
 
 
 
Figure 25 – Uptake of FITC-loaded PLGA and M-, MN- and Ms- PLGA nanoparticles by BMM after 20h of 
incubation. The results shown are representative of two independent experiments. 
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4.2.2.2. Uptake studies - fluorescence microscopy 
 
 
 
 
 
 
 
 
 
 
 
Figure 26– Internalization of uncoated (A), M- (B), MN- (C) and Ms- (D) coated PLGA nanoparticles, by 
BMM, after 20h of incubation. 
The images obtained by fluorescence microscopy demonstrate that all nanoformulations 
have an intracellular uptake after 20h incubation, evidenced by the presence of green 
fluorescence (FITC) within the cytoplasm. From the images it is possible to infer that in the 
case of uncoated (Fig.26A) and M-coated (Fig.26B) internalized PLGA nanoparticles the 
distribution pattern in the cytoplasm is more diffuse, whereas in cells that internalize MN- 
(Fig.26C) and Ms-coated (Fig.26D) PLGA nanoparticles small green dots are present 
distributed throughout the cytoplasm, which suggests that the uptake of these 
nanoparticles occurs by an endocytic way. 
4.2.3. In vitro BMM activation studies 
4.2.3.1. Cell surface markers 
Flow cytometry studies were performed to study in which way functionalization of PLGA 
nanoparticles with the different sugars (M, MN and Ms) influence the activation status of 
macrophages. For that BMM with 8 days of differentiation were used and co-cultured for 
20h with non-functionalized and M-, MN- and Ms-functionalized nanoparticles. The 
percentage of dead cells evaluated by FACS after staining with 7-AAD was 11.5%, being 
the expression of each cell surface marker reported as MFI of CD11b+/7-AAD- cells. 
In general, the results indicate that functionalization of PLGA nanoparticles with any of the 
three sugars, significantly enhanced the expression of co-stimulatory molecules 
A B 
C D 
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associated with the maturation of BMM: CD40 (Fig.27A, Fig.28), CD86 (Fig.27B, Fig.28) 
and CD80 (Fig.27C, Fig.28), MHC II (Fig.27D, Fig.28), a molecule involved in antigen 
presentation, and increase also the surface expression of MR (Fig.27E), the target 
receptor of this study, as compared to non-functionalized nanoparticles. An interesting 
result is that MN- and Ms- functionalized nanoparticles induce a statistically highly 
significant (P<0.001) expression of all surface markers, with exception for MHC II, as 
compared with M-PLGA nanoparticles, which suggest that these two sugars influence 
more significantly the activation and maturation of BMM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27 - Analysis of the surface expression of (A) CD40, (B) CD86, (C) CD80, (D) MHC II and (E) MR in 
BMM with 8 days of differentiation and isolated from a Balb/c mice. Nonstimulated (NS) and LPS stimulated 
cells were used as negative and positive control, respectively. BMM were also co-cultured with non-
functionalized PLGA nanoparticles (NF) and M-, MN- and Ms-functionalized PLGA nanoparticles. Results are 
expressed as the mean ± standard deviation of three independent experiments performed in duplicate.          
** P<0.01 and *** P<0.001 compared to NF; MFI – mean fluorescence intensity. 
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Figure 28 – Dot plots representing the surface expression of co-stimulatory molecules associated with 
macrophages maturation and antigen presentation, CD40, CD86, CD80 and MHC II, in BMM with 8 days of 
differentiation and isolated from a Balb/c mice. The results shown are representative of three independent 
experiments. 
 
4.2.3.2. Intracellular cytokines 
The efficiency with which functionalized nanoparticles induces macrophage activation and 
maturation could be assessed not only by the expression of co-stimulatory molecules but 
also by cytokines production. The production of cytokines could be evaluated by ELISA 
using cell-free supernatants, or by the determination of the production of intracellular 
cytokines. 
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Figure 29 - Analysis of the production of (A) IL-4, (B) IL-6, (C) IL-12 and (D) TNF-α in BMM with 8 days of 
differentiation and isolated from a Balb/c mice. Nonstimulated (NS) and LPS stimulated cells were used as 
negative and positive control, respectively. BMM were also co-cultured with non-functionalized PLGA 
nanoparticles (NF) and M-, MN- and Ms-functionalized PLGA nanoparticles. Results are expressed as the 
mean ± standard deviation of three independent experiments performed in duplicate. ** P<0.01 and              
*** P<0.001 compared to NF. 
BMM production of cytokines IL-4, IL-6, IL-12 and TNF-α were measured in cells 
untreated and treated with non-functionalized and manosylated PLGA nanoparticles. 
Results show that co-culture of BMM with PLGA nanoparticles functionalized with any of 
the three sugars, M, MN and Ms, increases statistically highly significant (P<0.001) the 
production of IL-6 and TNF-α ( ig.29B and D), in comparison with non-functionalized 
nanoparticles, being that, the greatest production of both pro-inflammatory cytokines was 
observed for cells co-cultured with Ms-PLGA nanoparticles. In what concerns the 
production of IL-4, a cytokine that induces the maturation of näive T cells to Th2 cells, it is 
possible observe in Fig.29A that BMM, even the ones co-cultured with nanoparticles, 
produced small percentages of these cytokine (<2%). Despite the fact that production of 
IL-4 is low, it is possible to observe that cells co-cultured with MN- and Ms-PLGA 
nanoparticles exhibit a statistically highly significant (P<0.001) production of these 
cytokine, when compared with non-functionalized nanoparticles and even with M-PLGA 
nanoparticles, that curiously is the one that less efficiently stimulates the production of IL-
4. The production of IL-12 (Fig.29C) is higher, when compared with IL-4 and, it follows the 
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same trend observed for that cytokine, being that, in this case, the higher production is 
observed for cells co-cultured with Ms-PLGA nanoparticles. These results suggest that 
PLGA nanoparticles functionalized with MN and Ms modulates more significantly the 
activation status of macrophages, with production of IL-6 and TNF-α, which is in 
accordance with the results presented in section 4.2.3.1.. 
4.2.4. MR expression in BMDCs 
The expression of the MR on different days of BMDCs differentiation was evaluated to 
determine the most suitable day to perform the following in vitro studies. The CD11c was 
used as a DC marker to quantify the percentage of BMDCs expressing MR between the 7 
and 9 day of differentiation. MHC II, a molecule highly expressed in mature DCs, was also 
assessed to gain additional information on the differentiation state of the cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30 - Dot plots showing (A) MR and (B) MHC II expression on days 7, 8 and 9 of murine bone-marrow 
derived DCs differentiation. Numbers in the upper right quadrant represent the percentage of CD11c
+
MR
+
 or 
CD11c
+
MHC II
+
cells. The results shown are representative of one experiment. 
No significant differences in MR expression were seen on different days of differentiation 
(Fig.30), and comparatively with BMM (Fig 23), BMDCs have a significantly lower 
expression of these receptor. However, in what concerns MHC II expression (Fig.30B and 
F) we observe that the expression of these molecule is time-dependent, being the 
maximum expression observed on day 9 of differentiation, with 68.1 % cells    
CD11c+/MHC II +. Thus, taking into consideration these results BMDCs with 9 days of 
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differentiation were used to conduct in vitro activation studies, since, although the 
expression of MR is almost the same for the three days of differentiation, the percentage 
of mature DCs is significantly higher. 
4.2.5. In vitro BMDCs activation studies 
4.2.5.1. Cell surface markers 
Flow cytometry was used to verify if mannosylated PLGA nanoparticles induce, as 
described in the literature [6, 140], the DC activation and maturation. For that BMDCs with 
9 days of culture were co-cultured during 20h with non-functionalized and M-, MN- and 
Ms-functionalized nanoparticles. The percentage of dead cells evaluated by FACS after 
staining with 7-AAD was 9.1%, being the expression of each cell surface marker reported 
as MFI of  CD11c+/7-AAD- cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31 - Analysis of the surface expression of (A) CD40, (B) CD86, (C) MHC II and (D) MR in BMDCs with 
9 days of differentiation and isolated from a Balb/c mice. Nonstimulated (NS) and LPS stimulated cells were 
used as negative and positive control, respectively. BMDCs were also co-cultured with non-functionalized 
PLGA nanoparticles (NF) and M-, MN- and Ms-functionalized PLGA nanoparticles. Results are expressed as 
the mean ± standard deviation of one experiment performed in duplicate. * P<0.05, **P<0.01, *** P<0.001 
compared to NF; MFI – mean fluorescence intensity. 
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Figure 32 – Dot plots representing the surface expression of co-stimulatory molecules associated with DCs 
maturation and antigen presentation, CD40, CD86 and MHC II, in BMDCs with 9 days of differentiation and 
isolated from Balb/c mice. The results shown are representative of one experiment performed in duplicate. 
 
Results show that PLGA nanoparticles functionalized with any of the three sugars 
significantly enhanced the expression of CD40 (Fig.31A and Fig.32) but not of CD86 
(Fig.31B and Fig.32), both co-stimulatory molecules associated with the maturation of 
DCs. Moreover the mannosylation led to a significant increase in the expression of MHC II 
(Fig.31C and Fig. 32), a molecule involved in antigen presentation, and MR (Fig.31D), 
when compared to non-functionalized nanoparticles. The high MFI values obtained for 
MHC II molecule (Fig.31C), in comparison with the values obtained for the co-stimulatory 
molecules and even for MR is consistent with the fact that this molecule has a large 
expression in BMDCs. Contrary to what happen with BMM, in this case the three sugars 
seem to stimulate equally the BMDCs activation and maturation. 
4.2.5.2. Intracellular cytokines 
As already mentioned for BMM, the efficiency with which functionalized nanoparticles 
induce DC maturation could be assessed not only by the expression of co-stimulatory 
molecules but also by cytokines production. 
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Figure 33- Analysis of the production of (A) IL-4, (B) IL-6 and (C) IL-12 in BMDCs with 9 days of 
differentiation and isolated from a Balb/c mice. Nonstimulated (NS) and LPS stimulated cells were used as 
negative and positive control, respectively. BMDCs were also co-cultured with non-functionalized PLGA 
nanoparticles (NF) and M-, MN- and Ms-functionalized PLGA nanoparticles. Results are expressed as the 
mean ± standard deviation of one experiment performed in duplicate. *** P<0.001 compared to NF. 
BMDCs production of cytokines IL-4, IL-6 and IL-12 were measured in cells untreated and 
treated with non functionalized and sugar-functionalized PLGA nanoparticles by flow 
cytometry. Results show that stimulation of BMDCs with PLGA nanoparticles 
functionalized with any of the three sugars increases statistically highly significant 
(P<0.001) the production of IL-4 (Fig.33A), in comparison to non-functionalized 
nanoparticles, being that the greatest production of this cytokine is observed for cells 
stimulated with Ms-functionalized nanoparticles. Results also suggest that LPS is not 
capable of stimulating the production of IL-4, since the percentage of cytokine produced is 
almost zero. Fig.33B shows that functionalized nanoparticles increased significantly the 
IL-6 production being that, in this case, the greatest production of this cytokine is 
observed for cells stimulated with M-functionalized nanoparticles. Contrary to the trend 
observed so far, in the case of IL-12 production (Fig.33C), the higher levels were 
observed when BMDCs are stimulated with non-functionalized PLGA nanoparticles, with 
values almost identical to those observed for positive control (LPS). Among cells 
stimulated with functionalized nanoparticles, the ones that stimulate more efficiently the 
production of IL-12 are those with mannose. 
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V. DISCUSSION 
5.1. Mannosylated nanoparticles for VL therapy 
AmB, an amphiphilic polyene antibiotic, constitutes a second line of treatment against VL 
with a high cure rate [141]. However, the use of this compound have some drawbacks, 
including the high toxicity, the high costs associated with its use, the limited availability in 
some areas, difficulties associated with the administration, prolonged duration of therapy 
and the severe side effects [1, 4]. Thus in order to improve AmB efficacy as an 
antileishmanial drug and reduce its toxicity a nanoparticulate system targeting MR in 
APCs (macrophages and DCs), the target cells in VL, was developed and characterized. 
5.1.1. Preparation and characterization of unloaded M-PLGA nanoparticles 
In order to functionalize PLGA nanoparticles with mannose different approaches can be 
conducted. Initially three different techniques, PA, CR1 and CR2 were evaluated through 
their physicochemical characterization and in vitro studies to define the most suitable 
technique for the preparation of M-PLGA nanoparticles. 
The use of nanoparticles as drug delivery systems implies that a systematic 
characterization is made, to verify if their properties are the most appropriate for the 
intended application. Size is the most important parameter in the characterization of a 
nanoparticulate system, since it will influence their release profile and degradation rate 
and also because, it is a major determinant of the uptake and biodistribution of 
nanoparticles [30]. Uncoated PLGA nanoparticles exhibited a mean diameter of         
205.5 ± 7.3 nm, being that the incorporation of mannose does not lead to a statistically 
significant alteration in size, with M-PLGA nanoparticles presenting a mean diameter in 
the range of 195.0 ± 8.2 – 221.9 ± 2.6 nm (Table 3). All nanoformulations have low PDI 
values (<0.1) (Table 3) which suggest that homogenous populations with a narrow size 
distribution were produced. 
Zeta potential is also an important parameter in the characterization of nanoparticles since 
it measures the surface charge of nanoparticles and gives information about their stability 
in a suspension, under defined conditions. In general, nanoparticles with high negative or 
positive values (≥ ± 30 mV) of zeta potential have a lower tendency to aggregate, due to 
electrical repulsion [16]. The negative surface charge of PLGA nanoparticles                    
(-12.5 ± 0.90 mV) increased significantly, in absolute value, after mannose incorporation 
by PA (-16.8 ± 0.01 mV) (P<0.05), CR1 (-27.0 ± 2.50 mV) (P<0.001) and CR2                  
(-22.2 ± 0.07 mV) (P<0.01) (Table 3), which is not in accordance with previous findings, in 
which a reduction in zeta potential, in absolute value, was observed after coating with the 
same ligand [29]. It is known that, negative zeta potential of PLGA nanoparticles is due to 
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the presence of terminal carboxylic groups (COOH). According to the literature [29], it was 
expected that conjugation of the COOH- groups with mannose induced a decrease in zeta 
potential, however in our case that was not verified. M-PLGA nanoparticles prepared by 
CR1 are those with a more negative zeta potential, which indicates that these 
nanoparticles have a higher electrical charge in their surface that leads to a strong 
repulsion between the particles and a lower tendency to form aggregates (low PDI value 
(0.036 ± 0.001)). Based on that and in the obtained results, M-PLGA nanoparticles 
prepared by CR1 seems to be the more stable suspension. 
The coating level of mannose was determined by indirect quantification of the ligand that 
was not adsorbed or chemically bound to PLGA, using the phenol-sulfuric acid reaction. 
Results demonstrate that an efficient coating of PLGA nanoparticles occur by any of the 
three techniques, being that the yields associated are around 94% (Table 3), which is not 
in accordance with data from literature [29]. Generally, the yields associated with 
mannose coating are much lower than the ones obtained in this work. This could be 
explained by the fact that in most articles, although the quantification method is the same, 
a direct measurement of mannose is made, which implies that mannose, physically or 
chemically incorporated, be effectively extracted through the use of techniques that 
requires the exposure of nanoparticles to harsh conditions, including high temperatures 
and organic solvents, leading to a great loss of the ligand, as a result of its destruction, 
and consequently the yields obtained will be lower. Thus the ideal would be to implement 
an alternative technique for quantification of mannose, like resorcinol sulfuric acid method 
[142], used as a complementary technique, to ensure that the yields obtained correspond 
to the real quantity of mannose that is present in the surface of nanoparticles. 
FTIR was used to confirm the conjugation of mannose to the PLGA nanoparticles, through 
the occurrence of a carbodiimide reaction that will favor the formation of a covalent 
binding between the polymer and the ligand. In the FTIR spectrum obtained for M-PLGA 
nanoparticles, prepared by CR1 and CR2 (Fig.13B) is observed a more prominent peak at 
1625 cm-1, not observed in the FTIR spectrum of uncoated PLGA nanoparticles (Fig.13A), 
that confirms the occurrence of a covalent bound between PLGA and mannose, being that 
these results are in agreement with the literature [29]. 
To study the presence and orientation of mannose in the surface of PLGA nanoparticles, 
an agglutination assay using ConA lectin was conducted (Fig.14). Although the levels of 
mannose present are similar for nanoparticles prepared by PA, CR1 and CR2, the results 
clearly demonstrate that ConA interact in a greater extent with mannose present in the 
ones prepared by CR. This different agglutination behavior suggests that, probably, as a 
result of the weak interaction, mannose, in nanoparticles prepared by PA, will be oriented 
to the core of the nanoparticles and less accessible in the surface to interact with ConA. 
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The in vitro evaluation of empty M-PLGA nanoparticles, prepared by PA, CR1 and CR2, 
revealed that the three nanoformulations do not exert cytotoxicity on human THP-1 
differentiated macrophages for concentrations up to 2 mg/ml (Fig.15). These results were 
expected since PLGA is a biodegradable, biocompatible and non-toxic polymer [12, 21]. 
Polymeric nanoparticles can be very useful in the treatment of leishmaniasis, due to its 
hydrophobic nature that allows their rapid uptake by macrophages, which are the main 
targets of Leishmania parasite, however they shouldn’t have immunogenic properties, in 
order to avoid the non-specific activation of macrophages. Previous studies demonstrate 
that empty polymeric nanoparticles may have antileishmanial activity as a result of their 
uptake by macrophages and consequent activation of effector mechanisms. Venier-
Julienne et al [143] have demonstrated, using an in vitro model of L.infantum infection, 
that empty PLGA nanoparticles are able, per se, to inhibit the growth of the parasite with 
the consequent release of hydrogen peroxide following the activation of macrophages. 
Another study report the same activity but for empty PACA nanoparticles [129]. Based on 
these facts it was important to verify if M-PLGA nanoparticles prepared by PA, CR1 and 
CR2 have immunogenic properties and are able, per se, to inhibit the growth of L.infantum 
intracellular amastigotes. The results obtained (Fig.16) indicate that nanoformulations do 
not have an inhibitory activity on parasite up to 2 mg/mL. Thus, it can be ensure that the 
antileishmanial activity observed when these nanoformulations are used as drug delivery 
systems is only due to the action of the drug. 
Physicochemical characterization and in vitro evaluation of M-PLGA nanoparticles have 
demonstrated that CR1 is the most suitable reaction for the preparation of mannosylated 
nanoparticles, since the nanoparticles obtained by this reaction present a size (195.0 ± 
8.2nm) adequate for animal administration, a low PDI (<0.1), good stability, were spherical 
in shape (Fig.12C), present more mannose groups oriented to the outer of the 
nanoparticle (Fig.14), and do not present toxicity against human THP-1 differentiated 
macrophages (Fig.15) or intracellular L.infantum amastigotes (Fig.16). The storage 
stability of chosen nanoparticles was then evaluated at different temperature conditions. 
5.1.2. Storage stability of unloaded M-PLGA nanoparticles prepared by CR1 
The storage of nanoparticles for long periods of time implies that the factors that could 
influence their stability should be controlled, including polymer properties (e.g. copolymer 
composition) and physicochemical properties (e.g. temperature, pH and ionic strength). It 
is described in the literature [144] that, more hydrophobic and crystalline polymers have 
slow degradation rates and consequently are more stable. Moreover, the stability of PLGA 
nanoparticles is influenced by the pH of the storage medium, since hydrolysis of ester 
groups is favored in acidic and basic media, as an example, the storage in a buffer with 
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pH 7.4 can slow their degradation and enhance their stability [144]. In this work a PLGA 
(70:30) polymer highly hydrophobic, as a result of the high percentage of lactic acid, is 
used and the nanoparticles are stored in PBS pH7.4. Another factor that influences 
significantly the storage stability of nanoparticles is temperature. Thus, the influence of 
different temperature conditions, -20⁰C, 4⁰C and 37⁰C, in the storage stability of M-PLGA 
nanoparticles was evaluated, in order to determine the most suitable conditions for 
storage of these nanoformulations. 
M-PLGA nanoparticles stored at 4⁰  don’t present significant changes in their size 
(Fig.17A), PDI (Fig.17B) and zeta potential (Fig.17C) over the 8 weeks of storage. On the 
other hand when storage assays are conducted at -20⁰C at the end of only 1 day a highly 
significant increase in size (Fig.17A) was observed, possibly due to particle aggregation, 
being that high PDI values (Fig.17B) reinforce this idea. In storage assays performed at 
37⁰C a significant increase in size and PDI (Fig.17A-B) is also observed, however is not 
as prominent as observed at -20⁰C. The zeta potential (Fig.17C) of nanoparticles stored at 
-20⁰C and 37⁰C becomes less negative with time, being that decreased more prominent 
for nanoparticles stored at 37⁰C. Thus, nanoparticles stored at these temperatures will 
have a greater tendency to aggregate, being the suspension less stable. 
The results from storage stability studies clearly demonstrate that the best storage 
temperature condition to maintain M-PLGA nanoparticles, prepared by CR1, for long 
periods of time is at 4⁰C. 
5.1.3. Preparation and characterization of AmB-loaded M-PLGA 
nanoparticles 
The previous developed mannosylated nanoparticles were used to encapsulate AmB and 
their efficiency as drug delivery system, in the treatment of VL, was evaluated in vitro in 
Leishmania-infected macrophages.  
AmB was successfully incorporated into uncoated PLGA nanoparticles by 
nanoprecipitation, a simple method usually employed to incorporate hydrophobic 
compounds into nanoparticles. Although we define CR1 as the most suitable reaction for 
the conjugation of mannose with PLGA nanoparticles, in this case, and in order to make a 
comparison in terms of physicochemical properties, mannose was both physically and 
chemically conjugated with nanoparticles. 
The incorporation of AmB in PLGA nanoparticles leads to a statistically significant 
increase in size, possibly due to an expansion of their matrix following encapsulation of 
the compound, which is in accordance with data from literature [29]. AmB-loaded PLGA 
nanoparticles exhibited a mean diameter of 208.0 ± 0.3 nm (Table 4), being that the 
mannose-coating of these nanoparticles by PA does not lead to a significant alteration in 
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size (200.2 ± 10.7 nm), however when CR1 is used a statistically significant decrease 
(190.8 ± 6.4 nm) (Table 4), which is not in accordance with what is described in the 
literature [29]. All nanoformulations have lower PDI values (<0.1) (Table 4), which suggest 
that different populations have a narrow size distribution. 
Zeta potential of PLGA nanoparticles is not significantly affected by the incorporation of 
AmB, which means that the compound has not influence in the surface charge of 
nanoparticles. On the other hand, the negatively surface charge of loaded nanoparticles  
(-12.6 ± 0.2 mV) increased significantly, in absolute value, after mannose incorporation by 
PA (-14.7 ± 0.2 mV) and CR1 (-16.2 ± 0.9mV) (Table 4), which is not, once again, in 
accordance with previous findings, in which a reduction in zeta potential, in absolute 
value, is observed after coating with the same ligand [29]. 
Similarly to what is observed previously for unloaded M-PLGA nanoparticles, also in  
AmB-loaded nanoparticles an efficient coating with mannose occur by PA and CR1, being 
that the yields associated are around 95% and 98%, respectively (Table 4). 
AmB encapsulation in uncoated and M-coated PLGA nanoparticles was determined 
directly by UPLC. An E.E. of 20% was achieved for uncoated PLGA nanoparticles, being 
that the coating of these nanoparticles with mannose, either by PA or CR1, lead to a 
significant decrease on the E.E., for values of 1.8% and 4.1%, respectively. The observed 
decreased in the E.E. could be explained by a saturation of the polymeric matrix as a 
result of the high drug loading (20%) used. Besides that, it is demonstrated that different 
physicochemical properties of AmB, including limited solubility in water and in most 
organic solvents, with the need to use DMSO as co-solvent, as well as its aggregatory 
nature, could contribute for its low encapsulation in polymeric nanoparticles [145]. So, in 
further studies, to try to increase the E.E. of AmB it would be interesting decrease 
significantly the drug loading, e.g. 1% and employ the principle of co-solvency [4, 145].  
Study of the mechanisms and physicochemical processes involved in drug release is 
important when we use polymeric nanoparticles, because of their application in sustained 
drug delivery. Release of AmB from M-PLGA nanoparticles, prepared either by PA or 
CR1, was determined over time at two pH conditions, 5.5, to simulate the release in the 
endosomal compartment of macrophages, and 7.4, to simulate the physiological 
conditions, and using two different buffers PBS and HEPES. Previous studies have 
demonstrated that in PLGA-based drug delivery systems, namely in the ones used for 
delivery of AmB, the drug release follows a biphasic pattern with an initial burst of release 
that are mainly controlled by mechanisms of diffusion, followed by a more slow and 
controlled liberation that occurs as a result of the polymer degradation [42, 146] (Lima, 
unpublished work). Despite the biphasic pattern is most common, some authors have 
already demonstrated that some drug delivery systems exhibited a triphasic release 
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profile [43-45, 147]. Although it has been demonstrated that AmB-loaded PLGA 
nanoparticles have a biphasic pattern (Lima, unpublished work), the coating of these 
nanoparticles with mannose, either by PA or CR1, leads to the exhibition of a triphasic 
release profile in all tested conditions (Fig. 19A-B), that include an initial moderate and 
continuous release of 15 to 20% of AmB, in the first 24 hours, caused by the controlled 
release of non-encapsulated drug molecules on the surface of nanoparticles; a second 
phase in which a fast release of about 30-40% occurs, in the following 6 days, that is more 
prominent in M-PLGA nanoparticles prepared by PA and which results from a swelling of 
PLGA by inward diffusion of water that will consequently favor the solubilization and rapid 
diffusion of AmB, either through the polymer or through the formed pores; and a last 
phase in which a sustained release of AmB was observed as a result of the slow polymer 
degradation, which means that the dissolution rate of the products formed as a result of 
the random scission of PLGA ester bonds and, the consequent creation of pores, through 
which AmB will diffuse, is very slow, as described on Fig 3. M-PLGA nanoparticles 
prepared by PA and CR1 have the same release profile (Fig.19A-B), however, for all 
experimental conditions, it is observed that nanoparticles prepared by CR1 have a slow 
and more controlled release of AmB (Table 5), which is in accordance with the fact of 
these nanoparticles have a much more stable structure resulting from the covalent bond 
between mannose and PLGA. Effectively, the less stable structure of nanoparticles 
prepared by PA, could explain the faster and significant release of AmB in the second 
phase of the release profile. Another interesting aspect is that M-PLGA nanoparticles 
prepared by both techniques present a significantly lower release of the compound when 
incubated in conditions that mimics the phagolysossomal compartment in macrophages 
(PBS pH5.0) (Table 5). 
Thus, these results suggest that the use of M-PLGA nanoparticles prepared by CR1, as 
drug delivery system, is more advantageous, when compared to the ones prepared by 
PA, since besides having a higher encapsulation efficiency, they also favor a slow and 
controlled release of AmB, especially in acidic conditions, as a result of their stable 
structure. 
The in vitro toxicity and efficacy of AmB and their nanoformulations were evaluated 
towards uninfected and L. infantum-infected macrophages (human THP-1 differentiated 
macrophages and BMM). Results show that free AmB exhibited toxicities to human  
THP-1 differentiated macrophages and BMM of 19.8 ± 3.6 µM and 21.8 ± 2.8 µM, 
respectively (Table 6). These elevated toxicities could be explained by the fact that even 
tough in a lesser extent, AmB interacts with cholesterol of host macrophages and can 
induce formation of pores leading to death of the cells, being these one of the possible 
mechanisms by which this compound cause cellular toxicity [1, 111, 148]. Encapsulation 
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of AmB on uncoated and M-coated PLGA nanoparticles significantly reduces its toxicity 
towards human THP-1 differentiated macrophages and BMM (Table 6). These results 
are in accordance with in vitro and in vivo studies, in which was demonstrated that 
encapsulation of a drug into a nanoformulation effectively reduce their toxicity [4, 129-
132]. 
Free AmB exhibit a higher antileishmanial activity against infected human THP-1 
differentiated macrophages (1329.2 ± 151.5 nM) and BMM (1134.6 ± 91.0 nM) (Table 7), 
being that, the incorporation of AmB into PLGA nanoparticles, increased significantly the 
efficacy of these compound in inhibiting intracellular amastigote growth in both types of 
cells, in comparison with free AmB (Table 7). On the other hand, when AmB is 
incorporated in M-PLGA nanoparticles, prepared either by PA or CR1, an improvement of 
the drug antileishmanial activity in the nanoformulations was also observed for both   
THP-1 cells and BMM (Table 7), being that nanoparticles prepared by CR1 seems to be 
more efficient in that effect, which could be associated with the slow and more controlled 
release observed in these nanoparticles. Thus, the functionalization of PLGA 
nanoparticles seems to favor a higher uptake of nanoparticles and consequently a higher 
antileishmanial activity. Since we have already demonstrated that M-PLGA nanoparticles 
are not able, per se, to inhibit the growth of L. infantum intracellular amastigotes, the 
growth inhibition observed should be promoted by AmB released from the M-PLGA 
nanoparticles. 
The results clearly have demonstrated that the use of polymeric nanoparticles, in 
particular the ones coated with mannose by CR1, for drug delivery of AmB is a good 
strategy, since they promote, as a result of a slow and sustained release, a significant 
reduction of the compound toxicity towards mammalian cells and, consequently allows the 
administration of higher doses in order to eliminate the parasite effectively. 
5.1.4. Preparation and characterization of FITC-loaded nanoparticles 
Encapsulation of FITC in PLGA nanoparticles was performed to produce fluorescently 
labeled nanoparticles, similar to the non-functionalized and mannosylated ones. To gain 
knowledge on the cell targeting of M-PLGA nanoparticles, ex vivo and in vivo studies were 
performed in splenocytes. On the other hand, in the second part of this work, to evaluate 
the immunotherapeutic effect of different mannosylated nanoformulations, in addition to 
the above mentioned nanoparticles, FITC-loaded MN- and Ms- coated PLGA 
nanoparticles were also prepared. 
FITC was successfully incorporated into uncoated PLGA nanoparticles by the 
nanoprecipitation method and the different sugars were chemically conjugated to 
nanoparticles, using CR1 technique. FITC-loaded PLGA nanoparticles exhibited a mean 
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diameter of 201.2 ± 7.5 nm that is not statistically significant altered by the coating with M 
and MN, however a significant decrease (P<0.05) of size occurs after Ms incorporation 
(184.0 ± 0.9 nm) (Table 8). In what concerns PDI values (Table 8), results show that 
although the coating of PLGA nanoparticles with M did not cause a significant change 
(0.063 ± 0.002), as compared with uncoated PLGA nanoparticles (0.057 ± 0.002), the 
incorporation of MN and Ms favors a statistically significant increase of these values 
(0.066 ± 0.004 (P<0.05) and 0.084 ± 0.004 (P<0.001), respectively) that is more 
prominent in the case of Ms. This could be explained by the fact that the surface charge of 
Ms-PLGA nanoparticles (-14.6 ±0.6 mV) is less negative when compared with M- and MN-
PLGA nanoparticles (-19.0 ± 1.1 and -18.0 ± 1.4, respectively) (Table 8), making them 
more prone to aggregate and present higher PDI values. 
The coating level of M, MN and Ms was determined by indirect determination of the 
quantity of each sugar that was not chemically bound to PLGA, using phenol-sulfuric acid 
reaction. Results demonstrate that an efficiently coating of nanoparticles, with M-, MN- 
and Ms-, occurs, being the yields associated around 98%, 91% and 99%, respectively 
(Table 8), which is not in accordance with data from the literature [8, 29, 149]. Generally, 
the yields associated with the incorporation of any of the three sugars are much lower 
than the ones obtained for us. For M- and MN-PLGA nanoparticles, in most of the articles 
a direct quantification, using the phenol-sulfuric acid reaction, is made, which could lead 
as already mentioned to a great loss of ligand, as a result of the harsh techniques used to 
extract it from the surface of nanoparticles, leading to the achievement of very low yields. 
In the case of Ms-PLGA nanoparticles, the low yields normally presented in the articles 
could also be related with a direct quantification, however in this case, another important 
factor could explain this difference and, that is the method used for quantification, the     
O-phthalaldehyde fluorimetric assay [149]. Thus, the ideal would be to use two different 
techniques to quantify the same sugar in order to guarantee that the yields obtained are 
consistent and correspond to the real quantity of sugar present in the surface of 
nanoparticles. 
FITC encapsulation was indirectly determined by quantification of the non-encapsulated 
amount that stays in the aqueous phase after particle recovery. An E.E. of around 56% 
was achieved in all prepared nanoformulations (Table 8). These results are in accordance 
with previous reports indicating that E.E. of hydrophobic compounds is higher when 
nanoparticles are prepared by the nanoprecipitation method, since this method will 
prevent the diffusion of the compound to the aqueous phase during particles 
formation[150]. The coating of PLGA nanoparticles, contrarily to what happens with AmB, 
does not lead to a significant decrease in the E.E. of FITC, which could be explained by 
the fact that the encapsulation of this compound is not dependent on the occurrence of an 
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interaction with COOH group of PLGA and, also by the fact that coating by CR1 leads to 
the formation of a stable structure that will favor the lost of only small quantities of FITC 
reaching good E.E.. 
Release of FITC from uncoated, M-, MN- and Ms-coated PLGA nanoparticles was 
determined, over time, at physiological conditions using PBS pH 7.4. A biphasic pattern 
release of FITC (Fig. 20) was observed for all nanoformulations, with an initial rapid 
release of about 3.2%, caused by the liberation of the drug deposited in the surface of 
nanoparticles, that is followed by a constant release during the rest of the incubation 
period, as a result of the constant diffusion of the compound through the channels that are 
created in the polymer matrix resulting from the inward diffusion of water and the onset of 
erosion [41]. The pattern of release presented by these nanoformulations suggest that, 
although FITC is not chemically bound, as a result of the stable structure of nanoparticles, 
the release will be very slow and controlled, giving the information that the intensity of 
fluorescence observed in posterior studies corresponds to the action of nanoparticle and 
not of the free compound. 
5.1.5. Ex vivo and in vivo uptake studies 
The use of mannose to improve the efficiency of a PLGA-based drug delivery system in 
the treatment of leishmaniasis was based on the fact that the target receptor of this ligand, 
MR, is highly expressed in APCs (macrophages and DCs). Thus, it is of great importance 
to verify if the developed nanoformulations are effectively internalized by the target cells. 
For that ex vivo and in vivo studies were conducted with splenocytes isolated from Balb/c 
mice and the uptake of nanoparticles by different types of cells, namely T cells (CD4+ and 
CD8+), B cells, APCs and neutrophils evaluated. Ex vivo studies (n=2) were initially 
conducted, to avoid unnecessary use of laboratory animals and, then identical 
experiments were translate to in vivo, in order to validated the results obtained under 
physiological conditions. Analysis of the cellular composition of splenocytes, both ex vivo 
and in vivo, revealed a predominance of lymphocytes, with a significant high number of    
B cells as compared with CD4+T and CD8+T cells, whereas APCs and neutrophils 
represent only a small percentage of total cells in spleen (Fig.21A-B and Fig.22A-B), 
which is in accordance with what is described in the literature [151]. Then, in order to 
study the uptake of FITC-loaded uncoated and M-coated PLGA nanoparticles by different 
types of cells, for the ex vivo studies splenocytes were co-cultured, for 24h, with a defined 
volume of each of nanoformulations and, for in vivo studies, Balb/c mice were 
administered with the same amount of the nanoformulations (Material and Methods, 
section 3.7.). In splenocytes co-cultured with FITC-loaded PLGA nanoparticles    
(Fig.21C-D), as well as in the ones isolated from mice treated with the same 
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nanoformulations (Fig.22C-D), it was observed that although lymphocytes constitute the 
main population of cells in spleen, the uptake occurs preferentially by APCs and 
neutrophils. On the other hand, the uptake profile of M-PLGA nanoparticles in the ex vivo 
experiments (Fig.21E-F) is different from the one observed in in vivo experiments 
(Fig.22E-F). In splenocytes co-cultured with M-PLGA nanoparticles, similarly to what is 
observed for the ones co-cultured with uncoated nanoparticles, the uptake occurs 
preferentially by APCs and neutrophils. In splenocytes isolated from Balb/c mice, 
contrarily to what would be expected, APCs present an uptake almost similar to what is 
observed for lymphocytes, with neutrophils being the cells with higher uptake of M-PLGA 
nanoparticles. These results could be explained by the fact of mannosylated 
nanoparticles, after their administration, be first internalized by the APCs present in the 
liver, since they will pass through this organ before they reach the spleen. In that way, it 
would be interesting, in further studies, evaluate the uptake of nanoparticles, both ex vivo 
and in vivo, by the cells present in the liver. Results for both ex vivo and in vivo studies 
have demonstrated that neutrophils are the cells in which a higher uptake of nanoparticles 
was observed, since they are the most abundant population of circulating leucocytes and 
are rapidly recruited to the infected sites mediating the initial stages of an inflammatory 
response [151]. It is also important to note that the number of cells containing FITC-
loaded nanoparticles is higher in ex vivo studies, which is expected since in vivo there is 
the influence of other cells and other mechanisms that could interfere with the uptake of 
these nanoparticles, leading to a lower number of particles retained by the spleen cells. 
Although the development of a mannosylated nanoparticulate system aims to increase the 
uptake by APCs, through the targeting of MR, that is highly expressed in these cells, the 
ex vivo results demonstrate that there is no significant differences in the uptake of 
uncoated and M-coated PLGA nanoparticles by these cells (Fig 21C-F). PLGA 
nanoparticles are internalized mainly through clathrin-mediated endocytosis, although by 
the fact of them, in contrast with M-PLGA nanoparticles, do not have a ligand targeting 
MR, allows their internalization by other mechanisms such as phagocytosis or fluid-phase 
endocytosis [24]. M-PLGA nanoparticles, on the other hand, target specifically MR that 
mediates the internalization and deliver through clathrin-mediated endocytosis (Fig.7), 
being that this receptor doesn’t seems to be able, per se, to mediate phagocytosis [66, 
84]. Thus the similar uptake observed for uncoated and M-coated PLGA nanoparticles 
could be explained by the fact of while mannosylated nanoparticles are internalized only 
through the endocytic pathway, uncoated nanoparticles can be internalized by different 
mechanisms favoring an uptake by APCs similar to that observed for functionalized 
nanoparticles. 
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Ex vivo results strongly suggest that targeting APCs through the use of a ligand, such as 
mannose, that is specifically recognized by MR, seems to be a good strategy to improve 
the efficiency of PLGA-based drug delivery systems in the treatment of leishmaniasis. 
However, in further studies, it is necessary to repeat in vivo experiments to confirm the 
preferentially uptake of mannosylated nanoparticles by APCs using fluorescence 
microscopy of several tissues. 
5.2. Mannosylated nanoparticles for immunotherapy 
Functionalization of nanoparticles with ligands that are targeted to specific receptors on 
APCs (macrophages and DCs), can potentially improve their immunotherapeutic effect, 
through the induction of a robust immune response [6-7, 140]. Specifically, targeting of 
MR, a member of CLR family highly expressed on DCs and macrophages, seems to be a 
good strategy to improve the efficiency of PLGA-based drug delivery systems, since this 
receptor is involved in antigen internalization and presentation to immune response [91-
92]. Recent studies, have demonstrated that functionalization of nanoparticles with ligands 
that are specifically recognized by MR induces the activation and maturation of DCs, 
which is evidenced by the enhanced expression of cell surface markers, including CD40, 
CD80, CD86 and MHC II and by the higher production of pro-inflammatory cytokines (IL-6, 
IL-12 and TNF-α) [6, 140]. Thus, since MR-targeting can be a promising approach to 
improve the immunotherapeutic effect of nanoformulations, the second aim of this work 
was using PLGA nanoparticles functionalized with three different ligands (M, MN, Ms) that 
have a strong binding affinity to MR, evaluate the extent in which these mannosylated 
nanoformulations affect the activation status of the cells and the type of response that 
they will modulate in APCs. These studies were performed in macrophages, since no 
published studies evaluating the immunotherapeutic potential of nanoformulations in these 
cells were found in literature and, also in DCs to validate the system with data from the 
literature [6, 8, 140, 152]. 
The expression of MR on different days of BMM differentiation was assessed, in order to 
define the most suitable day to perform the in vitro uptake and activation studies. The 
results have shown that the expression of this receptor is time-dependent, with a 
maximum expression at day 8 of differentiation (77.9% cells F4/80+ / MR+) (Fig 23A-B). 
Interestingly, a significant decrease in the expression of the receptor was observed from 
day 8 to day 9 (Fig.23A), which could be explained by a down-regulation of the 
mechanisms involved in MR expression as result of aging of cells. Thus, based on these 
results the following in vitro studies were performed at day 8 of BMM differentiation. 
Then, uptake studies of fluorescently labeled uncoated and M-, MN- and Ms-coated PLGA 
nanoparticles were conducted to see if these nanoparticles have a differential uptake in 
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BMM, if this is time-dependent and to define the most suitable time of incubation that 
should be used in subsequent in vitro studies. The data on Fig.24A-D shows that            
30 minutes of incubation with the nanoparticles is sufficient to have a good fluorescence 
signal, since after that time, ≈90% of all nanoparticles had already been internalized by 
BMM. Nevertheless, to assure that nanoparticles are co-cultured with cells enough time 
to induce a detectable effect, a 20h incubation period was used in the posterior activation 
studies (Fig 24) [8]. The analysis of differential uptake of nanoparticles after an incubation 
period of 20h (Fig.25) suggests that uncoated PLGA nanoparticles have a higher uptake 
compared to mannosylated nanoparticles. PLGA nanoparticles are internalized mainly 
through clathrin-mediated endocytosis, although by the fact of them, in contrast with M-
PLGA nanoparticles, do not have a ligand targeting MR, allows their internalization by 
other mechanisms such as phagocytosis or fluid-phase endocytosis [24]. Funtionalized 
nanoparticles, on the other hand, target specifically MR that mediates the internalization 
and deliver through clathrin-mediated endocytosis (Fig.7), being that this receptor doesn’t 
seems to be able, per se, to mediate phagocytosis [66, 84]. Thus these facts could explain 
the differential uptake observed at 20h between uncoated and M-, MN- and Ms-coated 
PLGA nanoparticles. Another possible explanation for the differential uptake of uncoated 
and mannosylated PLGA nanoparticles is related with the fact of although the E.E. of 
FITC is equivalent for all the nanoformulations, the presence of different sugars in the 
surface of nanoparticles could mask the fluorescence of the compound. 
In order to confirm that all nanoparticles are efficiently internalized by BMM and also to 
have an idea of their distribution in cells, fluorescence microscopy was used. The results 
(Fig.26A-D) clearly show that, similar to what is observed in the in vitro uptake studies, all 
nanoparticles are efficiently internalized. These images also show that, although all 
nanoparticles are located in the cytoplasm, their distribution pattern is different, whereas 
non-functionalized (Fig.26A) and M-functionalized (Fig.26B) PLGA nanoparticles have a 
more diffuse distribution pattern, MN- (Fig.26C) and Ms-functionalized (Fig.26D) 
nanoparticles seems to be internalized in vesicles, which is evidence by the presence of 
green dots in the cytoplasm, suggesting that their uptake occurs by an endocytic pathway. 
Future studies will detailed the different distribution patterns of each nanoformulation, 
namely through the use of fluorescent endocytic markers (e.g.Lysotrack) clarifying the 
intracellular trafficking of these manosylated nanoformulations. 
Since macrophages, contrary to DCs, do not have a constitutive expression of migratory 
(MHC II) and co-stimulatory molecules (CD40, CD80 and CD86), they need to be 
previously activated to express these molecules [152]. Thus, through determination of the 
expression of specific cell surface markers is possible to assess the influence of non-
functionalized and M-, MN, and Ms- functionalized PLGA nanoparticles in the activation 
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status of macrophages. Results show that functionalization of PLGA nanoparticles with 
any of the three sugars leads to a statistically significant increase in the expression of 
CD40, CD86, CD80, MHC II (Fig. 27A-D and Fig.28) and MR (Fig.27E), when compared 
to non-functionalized nanoparticles. While M-functionalization favors a moderate 
activation of macrophages, the functionalization with MN and Ms induces a higher surface 
expression of migratory (MHC II) (Fig.27D and Fig.28) and co-stimulatory molecules 
(CD40, CD86 and CD80) (Fig.27A-C and Fig.28) and also of MR (Fig.27E), influencing 
more significantly the activation and maturation of macrophages and consequently the 
efficient activation of T cells. Therefore, MHC II, a molecule involved in antigen 
presentation to CD4+T cells; CD40, CD80 and CD86, co-stimulatory molecules that are 
specifically recognized by receptors in T cells surface and are essential for the activation 
and differentiation of CD4+T cells; and MR, that is involved in antigen uptake and 
processing, have all an important role in the formation of an adaptive immune response 
[152]. 
Although the expression of MHC II, CD40, CD80 and CD86 in macrophages is essential it 
is not sufficient to an induction of T cell activation. Thus, it is crucial that the activation of 
macrophages lead to the production of different cytokines, in order to favor the 
development of a more effective immune response. The profile of cytokines produced by 
BMM co-cultured with non-functionalized and functionalized nanoparticles was assessed 
through determination of the production of intracellular cytokines, including IL-4, IL-6, IL-
12 and TNF-α (Fig.29A-D). The results reveal that, similar to what is observed for cell 
surface markers, MN- and Ms-PLGA nanoparticles are the nanoformulations that 
stimulate more efficiently the activation of macrophages, which is reflected by the higher 
production of intracellular cytokines, IL-4, IL-6, IL-12 and TNF-α, being that TN -α 
(Fig.29D) is the one with higher production. IL-4 stimulates the maturation of näive T cells 
in Th2 cells and is an important autocrine growth factor for these newly formed cells [151]. 
Furthermore, it was described that this cytokine together with IL-13, promote an up-
regulation of MR and MHC II molecules, stimulating endocytosis and antigen presentation, 
and thus favoring an alternative activation of macrophages [153]. Thus, despite this 
cytokine being produced in small amounts (<2%), the higher production induced by MN- 
and Ms-PLGA nanoparticles (Fig.29A) could be in part related with the higher expression 
of MHC II and MR observed when BMM are co-cultured with these nanoformulations 
(Fig.27D and 27E). IL-6 has pleiotropic effects on cell growth, differentiation, survival and 
migration during immune responses, acting also as B cell differentiation factor [151]. On 
the other hand, TNF-α is also a pleiotropic cytokine whose main physiological function is 
the recruitment of phagocytes to the infection sites and consequent activation of these 
cells [151]. This cytokine act together with IFN-ɣ to promote the classical activation of 
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macrophages [155]. IL-12 is a stimulatory cytokine that drives Th1 responses associated 
with generation of cellular immunity [151]. Having said that, the higher production of IL-6, 
IL-12 and TNF-α (Fig.29A, C-D), as compared with the production of IL-4 (Fig.29B), 
observed when BMM are co-cultured with MN- and Ms- functionalized nanoparticles, 
suggest that these nanoformulations have a pro-inflammatory profile and that 
macrophages might be activated by the classical pathway. 
Thus, these results clearly demonstrate that functionalization of PLGA nanoparticles with 
MN and Ms improve their immunotherapeutic effect, through the induction of a more 
efficient activation of macrophages, which could lead to the development of a robust 
immune response. 
The fact of PLGA nanoparticles functionalized with MN and Ms stimulate more efficiently 
the activation of macrophages, which is reflected by the higher expression of cell surface 
markers and by the production of intracellular cytokines, could be related to a greater 
internalization of these nanoparticles, as compared to non-functionalized and M-
functionalized ones. However results from the uptake studies (Fig.24A-D, and Fig.25) 
shows that all nanoparticles are efficiently internalized by BMM, being that the non-
functionalized ones seems to have even a greater uptake. So, taken togheter these 
results suggest that although internalization is an important factor it will not be sufficient to 
enhance macrophages activation.  
The studies evaluating the immunotherapeutic potential of nanoformulations specifically 
targeting MR are described in DCs [6, 8, 140, 152]. In that way and, in order to validate 
the system used with BMM with the data from literature, the extent in which the 
developed nanoparticles affect the activation status of DCs was evaluated. 
Since the data from the literature relative to the day of BMDCs differentiation in which the 
MR expression is higher are contradictory, some authors consider day 7 [8] and others 
consider day 9 [6], initially the MR expression was evaluated on different days of BMDCs 
differentiation. In this case and since at day 6 less than 22% of cells are DCs the 
assessment was made between day 7 and 9 of BMDCs differentiation (Fig.30A). The 
MHC II expression (Fig.30B) was also quantified, since this is a molecule highly 
expressed in mature DCs, giving information about the differentiation/maturation state of 
these cells. The data obtained show no significant differences on the levels of MR 
expression (Fig.30A) but, the expression of MHC II (Fig.30B) increased significantly with 
time being the maximum expression observed at day 9 (68.1% cells CD11c+/MHC-II+). 
Thus, BMDCs with 9 days of differentiation was chosen, to perform posterior in vitro 
studies, since the high percentage of mature DCs was observed at that day. 
As already mentioned, the functionalization of nanoparticles with ligands that are 
specifically recognized by MR induces the activation and maturation of DCs, which is 
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evidenced by the enhanced expression of cell surface markers and by the higher 
production of pro-inflammatory cytokines [6, 140]. Thus, to verify if PLGA nanoparticles 
functionalized with M, MN and Ms induce the same results, the expression of cell surface 
markers as well as the production of intracellular cytokines in BMDCs co-cultured with 
those nanoformulations was evaluated. The results show that both non-functionalized and 
functionalized PLGA nanoparticles enhanced the expression of CD40 (Fig.31A and 
Fig.32), CD86 (Fig.31B and Fig.32), MHCII (Fig.31C and Fig.32) and MR (Fig.31D) when 
compared to non-stimulated BMDCs. Contrarily to what is observed for BMM, in BMDCs 
the functionalization of PLGA nanoparticles with any of the three sugars influence in the 
same way the activation and maturation of cells. The high MFI values obtained for MHC II 
molecule (Fig.31C), in comparison with the values obtained for the co-stimulatory 
molecules are in accordance with previous studies in which were demonstrated that at 
day 9 DCs are completely maturated and differentiated (Fig.30B). On the other hand the 
lower values of MFI obtained for MR is in accordance with the results obtained for the 
evaluation of the expression of this receptor on different days of BMDCs differentiation 
(Fig.30A), in which, was observed that even at day 9 the expression of these receptor was 
very low. Comparing the MFI values of antigen presenting and co-stimulatory molecules 
obtained for BMM and BMDCs co-cultured with the same type of nanoparticles is 
possible observe that they are higher for BMDCs, which may be related with the fact of 
these cells are the only APCs that constitutively express these molecules and, so the 
stimulation of these cells will enhance even more their expression. The results obtained 
are in accordance with data from the literature [6, 140], which means that the system used 
with BMM is suitable to evaluate the extent in which mannosylated nanoformulations 
affect the activation status of cells 
The profile of cytokines produced by BMDCs co-cultured with non-functionalized and 
functionalized nanoparticles was assessed through determination of the production of 
intracellular cytokines, including IL-4, IL-6 and IL-12. Results show that stimulation of 
BMDCs with PLGA nanoparticles functionalized with any of the three sugars increased 
statistically significant the production of IL-4 (Fig.33A) and IL-6 (Fig.33B). It was 
demonstrated that the exposure of DCs to certain stimulus (e.g.retrovirus) results in the 
intracellular production, but not in secretion of IL-4 [155]. Thus, based on that, the fact of 
functionalized nanoparticles stimulates a higher intracellular production of IL-4 (Fig.33A) 
by BMD s, doesn’t mean that this cytokine will be secreted and will, consequently, 
stimulate the maturation of näive T cells in Th2 cells. In that way, it will be important in 
further studies, to quantify the secreted cytokines. DCs are the major cells contributing for 
IL-12 production in primary immune responses, being that the production of this cytokine, 
in addition to the enhanced expression of co-stimulatory and antigen presenting 
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molecules, an important factor for the induction of efficient T cell activation [156]. In what 
concerns the production of this cytokine, results demonstrate that the co-culture of 
BMDCs with non functionalized PLGA nanoparticles, leads to the production of higher 
levels of IL-12 (Fig.33 C), as compared with functionalized nanoparticles, reaching values 
almost identical to those observed for LPS (positive control). When we are evaluating the 
effect of different nanoformulations in the activation status of a cell, besides the production 
of cytokines, it is also crucial to assess the expression of co-stimulatory and antigen 
presenting molecules. Thus, in that way, although it was observed that non functionalized 
PLGA nanoparticles induces a higher intracellular production of IL-12 (Fig.33C), an 
important cytokine in the development of an immune response, the fact of M-, MN- and 
Ms-functionalized nanoparticles induce a higher expression of CD40, CD86, MHC II 
(Fig.31A-C and Fig. 32) and MR (Fig.31D) as well as the production of IL-12 (Fig.33C), 
even at lower levels, and IL-6 (Fig.33B), make them more effective nanoformulations in 
the activation and maturation of BMDCs. Although the production of cytokines is important 
to evaluate the efficiency with which nanoformulations induces DC activation these results 
cannot be compared with data from the literature [6, 140] to validate the system adopted, 
since the methods used for evaluate the cytokines productions are different (usually the 
measurement is based on secreted cytokines). 
To summarize, the functionalization of PLGA nanoparticles with ligands that are 
specifically recognized by MR in APCs, particularly with MN and Ms, improve their 
immunotherapeutic effect, through the induction of a more efficient activation of 
macrophages and DCs, which could lead to the development of a robust immune 
response. Therefore, in order to complement these studies it would be interesting to 
evaluate the ability of these nanoformulations to stimulate specific CD4+ and CD8+ - T 
cells responses. 
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VI. CONCLUSIONS 
The novel nanoformulations developed in the present work, through the functionalization 
of the surface of PLGA nanoparticles with mannose residues, constitutes a promising 
strategy for efficient delivery of AmB and seems to have potential as immunotherapeutic 
agents in the treatment of VL. 
It was demonstrated that mannosylation of PLGA nanoparticles can be efficiently 
achieved by a simple chemical reaction (CR1), once the M-PLGA nanoparticles obtained 
by this reaction, in comparison with the ones prepared by PA and CR2, present a small 
size (< 200 nm), a low PDI (<0.1), good storage stability, were spherical in shape, have 
higher mannose residues oriented to the exterior of the NP, and do not present toxicity 
against human THP-1 differentiated macrophages and intracellular L.infantum 
amastigotes. 
The results from storage stability studies clearly demonstrate that the best storage 
temperature condition to maintain M-PLGA nanoparticles for long periods of time (8 
weeks) is at 4⁰C. 
The mannosylated nanoparticulate system, prepared by PA and CR1, were used to 
encapsulate AmB and their efficiency as drug delivery system, in the treatment of VL, was 
evaluated in vitro in Leishmania-infected macrophages. The use of AmB-loaded M-PLGA 
nanoparticles, prepared by CR1, as drug delivery system, is more advantageous, when 
compared to the ones prepared by PA, since besides having a higher encapsulation 
efficiency, they also favor a slow and controlled release of the compound, especially in 
acidic conditions, as a result of their stable structure. In line with previous in vitro and in 
vivo studies [4, 129-132], this work demonstrate that incorporation of AmB in uncoated 
and M-coated PLGA nanoparticles effectively reduce its toxicity towards macrophages, 
which is of great relevance, since this allows the in vivo administration of higher doses of 
AmB, without the toxic effects normally associated with the administration of the free 
compound. On the other hand, the encapsulation of AmB in M-PLGA nanoparticles, 
prepared either by PA or CR1, also improves it antileishmanial activity, being this effect 
more pronounced in nanoparticles prepared by CR1, which could be explained by the 
slow and more controlled release observed in this case. 
The results from ex vivo and in vivo studies performed in order to evaluate the M-PLGA 
nanoparticles uptake, demonstrate that although lymphocytes constitute the main 
population of cells in spleen, the uptake occurs preferentially by APCs (macrophages and 
DCs), the target cells in VL, and neutrophils. 
In the second part of the work it was demonstrated that the functionalization of PLGA 
nanoparticles with ligands that specifically target MR in APCs, particularly with MN and 
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Ms, improve their immunotherapeutic effect, through the induction of a more efficient 
activation of macrophages and DCs, evidenced by the enhanced expression of cell 
surface markers, including CD40, CD80, CD86 and MHC II and by the higher production 
of pro-inflammatory cytokines (IL-4, IL-6, IL-12 and TNF-α), which could lead to the 
development of a robust immune response. 
To summarize, the results from this work have demonstrated that mannosylated 
nanoformulations, in particular the ones prepared by CR1, could have a promising role in 
the delivery of AmB and consequently in the treatment of leishmaniasis. Furthermore, the 
use of nanoformulations functionalized with ligands that specifically target MR in APCs 
seems to promote the development of a robust immune response. 
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VII. FUTURE PERSPECTIVES 
In the last years the research interest in the area of developing nanotechnology suffered a 
huge growth. In particular, the application of polymeric nanoparticles as drug delivery 
systems in the treatment of different diseases, including leishmaniasis, has been 
extensively investigated, in an attempt to reduce toxicity and side effects of drugs 
currently used [130-132]. Thus, this work arises from the need to create a nanoparticulate 
system that overcome some of the main drawbacks associated with AmB, one of the more 
effective drugs used in the treatment of leishmaniasis, and that allows a more efficient 
delivery of these drug. Besides that, it is of great importance to understand in which extent 
the developed nanoformulations interfere/interact with the host immune system. In my 
point of view the results obtained in this work, to date, could contribute, in the future, to 
the development of a treatment capable of complement the ones that are currently 
available, however much work remains to be done. 
In further studies, it will be important evaluate the in vivo biodistribution pattern and the 
targeting potential for macrophage-rich organs of the developed nanoparticulate system, 
in comparising with free AmB, using healthy Balb/c mice. Furthermore, the in vivo efficacy 
of the nanoformulations should be evaluated against VL, using Balb/c mice previously 
infected with L.infantum as model. 
Since ex vivo and in vivo studies clearly demonstrate that M-PLGA nanoparticles are 
preferentially taken by APCs, in further studies it would be interesting to verify, both ex 
vivo and in vivo, if the immunological state of the mice influence in some way the uptake 
of nanoparticles by APCs, through the use of splenocytes isolated from non-infected and 
L.infantum-infected Balb/c mice. To complement these studies and confirm the obtained 
results, we can use immunohistochemistry techniques in order to evaluate the 
biodistribution of nanoparticles among different organs and their differential uptake by 
lymphocytes, APCs and neutrophils. 
In the second part of this work it was demonstrated that functionalization of PLGA 
nanoparticles with ligands that specifically target MR in APCs, induce a more efficient 
activation of macrophages and DCs. Therefore, in order to complement these studies we 
need to evaluate the ability of these nanoformulations to stimulate specific CD4+ and  
CD8+ - T cells responses (Th1 and Th2 responses). On the other hand, since the results 
obtained strongly suggest that MN and Ms are more effective than M in the induction of an 
immunological response, it would be interesting to do a comparative ex vivo and in vivo 
study of the differential uptake of those nanoformulations in lymphocytes (CD4+ and CD8+ 
and B), APCs and neutrophils. Furthermore, if we verify that in fact the nanoformulations 
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functionalized with MN and Ms are more effective, we can encapsulate AmB and evaluate 
their in vitro and in vivo efficacy in the treatment of VL. 
The fluorescence studies performed to evaluate the uptake of non functionalized 
and M-, MN- and Ms- functionalized PLGA nanoparticles by BMM lead us to hypothesize 
that nanoparticles functionalized with MN and Ms are internalized by an endocytic 
pathway. Thus, in further studies it would be interesting study in more detail the different 
distribution patterns of each nanoformulation, namely through the use of fluorescent 
endocytic markers (e.g.Lysotrack). 
Finally in order to verify if the increased activation of macrophages and DCs, 
induced by functionalized nanoparticles, are directly correlated with MR-ligand interaction 
and occurs via receptor-mediated encodytosis or by other mechanism, such as 
phagocytosis, we can perform in vitro studies in which MR, endocytosis and/or 
phagocytosis are inhibited. 
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